

Box 809

Approved for use through 09/30/2000. OMB 0661-0001  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <i>(Only for new nonprovisional applications under 37 C.F.R. § 1.53 (b))</i>		Attorney Docket No.	6627-PA11
		First Inventor or Application Identifier	Judith A. Varner
		Title	METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS
		Express Mail Label No.	EM432835166US

<b>APPLICATION ELEMENTS</b> See MPEP chapter 600 concerning utility patent application contents.		<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i>		5. <input type="checkbox"/> Microfiche Computer Program (Appendix)	
2. <input checked="" type="checkbox"/> Specification <i>(preferred arrangement set forth below)</i> [Total Pages <input type="text" value="66"/> ] -Descriptive title of invention -Cross References to Related Applications -Statement Regarding Fed sponsored R & D -Reference to Microfiche Appendix -Background of the Invention -Brief Summary of the Invention -Brief Description of the Drawings (if filed) -Detailed Description -Claims(s) -Abstract of the Disclosure		6. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i> a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies	
3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <input type="text" value="1"/> ] 4. Oath or Declaration [Total Pages <input type="text" value="2"/> ] a. <input checked="" type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63 (d)) <i>(for continuation/divisional with Box 16 completed)</i> i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed Statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b)		<b>ACCOMPANYING APPLICATION PARTS</b> 7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 8. <input type="checkbox"/> 37 CFR §3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i> 9. <input type="checkbox"/> English Translation Document <i>(if applicable)</i> 10. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 11. <input type="checkbox"/> Preliminary Amendment 12. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 13. <input type="checkbox"/> *Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired <i>(PTO/SB/09-12)</i> 14. <input type="checkbox"/> Certified copy of Priority Documents(s) <i>(if foreign priority is claimed)</i> 15. <input type="checkbox"/> Other:	

**\*NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).**

16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior Provisional Application No: 60/084,850

Prior application information: Examiner \_\_\_\_\_ Group / Art Unit \_\_\_\_\_

**For CONTINUATION or DIVISIONAL APPS only:** The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

<b>17. CORRESPONDENCE ADDRESS</b>					
Name	BROWN, MARTIN, HALLER & McCLAIN, LLP				
Address	1660 UNION STREET				
City	SAN DIEGO, CALIFORNIA 92101-2926				
Country	USA	Telephone	(619) 238-0999	Fax	(619) 238-0062

Name (Print/Type)	Richard J. Imbra	Registration No. (Attorney/Agent)	37,543
Signature	<i>Richard J. Imbra</i>	Date	May 7, 1999

A P P L I C A T I O N

for

UNITED STATES LETTERS PATENT

on

METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS

by

Judith A. Varner

Sheets of Drawings: One  
Docket No.: 6627-PA11

Attorneys  
BROWN MARTIN HALLER & McCLAIN, LLP  
1660 Union Street  
San Diego, California 92101-2926

## METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS

This application claims the benefit of priority of United States Provisional Application Serial No. 06/084,850 to Judith A. Varner, filed May 8, 1998, and entitled A NOVEL METHOD FOR THE DETECTION AND INHIBITION OF ANGIOGENESIS, the entire contents of which is incorporated herein by reference.

This invention was made, in part, with government support under grant number R01 CA71619 awarded by the National Cancer Institute. The government has certain rights in the invention.

### BACKGROUND OF THE INVENTION

#### FIELD OF THE INVENTION

This invention relates generally to methods for detecting and treating conditions involving undesirable angiogenesis and more specifically to methods of detecting or inhibiting angiogenesis by interfering with specific binding of  $\alpha 5 \beta 1$  integrin to a ligand.

#### BACKGROUND INFORMATION

Angiogenesis is the process whereby new blood vessels are formed. Angiogenesis, also called neovascularization, occurs normally during embryogenesis and development, and occurs in fully developed organisms during wound healing and placental development. In addition, angiogenesis occurs in various pathological conditions, including in ocular diseases such as diabetic retinopathy and macular degeneration due to neovascularization, in conditions associated with tissue inflammation such as rheumatoid arthritis and inflammatory bowel disease, and in cancer, where blood

vessel formation in the growing tumor provides oxygen and nutrients to the tumor cells, as well as providing a route via which tumor cells metastasize throughout the body.

Since millions of people around the world are afflicted by  
5 these diseases, a considerable effort has been made to understand the mechanisms involved in angiogenesis in the hope that such an understanding will allow the development of methods for detecting and inhibiting such undesirable angiogenesis.

10           Angiogenesis occurs in response to stimulation by one or more known growth factors, and also may involve other as yet unidentified factors. Endothelial cells, which are the cells that line mature blood vessels, normally do not proliferate. However, in response to an  
15 appropriate stimulus, the endothelial cells become activated and begin to proliferate and migrate into unvascularized tissue, to form new blood vessels. In some cases, precursor cells can be activated to differentiate into endothelial cells, which form new blood vessels.

20           Blood vessels are surrounded by an extracellular matrix. In addition to stimulation by growth factors, angiogenesis depends on interaction of the endothelial cells with the extracellular matrix, as well as with each other. The activation of endothelial cells  
25 by growth factors and the migration into and interaction with the extracellular matrix and with each other is dependent on cell surface receptors expressed by the endothelial cells. These cell surface receptors, which include growth factor receptors and integrins, interact  
30 specifically with particular molecules.

In pathological conditions such as age-related macular degeneration and diabetic retinopathy, decreasing availability of oxygen to the retina results in a hypoxic condition that stimulates the secretion of angiogenic growth factors such as vascular endothelial growth factors (VEGF), which induce abnormal migration and proliferation of endothelial cells into tissues of the eye. Such vascularization in ocular tissues can induce corneal scarring, retinal detachment and fluid accumulation in the choroid, each of which can adversely affect vision and lead to blindness.

Angiogenesis also is associated with the progression and exacerbation of inflammatory diseases, including psoriasis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. In inflammatory arthritic disease, for example, influx of lymphocytes into the region surrounding the joints stimulates angiogenesis in the synovial lining. The increased vasculature provides a means for greater influx of leukocytes, which facilitate the destruction of cartilage and bone in the joint. Angiogenic vascularization that occurs in inflammatory bowel disease results in similar effects in the bowel.

The growth of capillaries into atherosclerotic plaques in the coronary arteries represents another pathological condition associated with growth factor induced angiogenesis. Excessive blood flow into neovascularized plaques can result in rupture and hemorrhage of the blood-filled plaques, releasing blood clots that can result in coronary thrombosis.

The involvement of angiogenesis in such diverse diseases as cancer, ocular disease and inflammatory diseases has led to an effort to identify methods for specifically inhibiting angiogenesis as a means to treat these diseases. For cancer patients, such methods of treatment can provide a substantial advantage over currently used methods such as chemotherapy, which kill or impair not only the target tumor cells, but also normal cells in the patient, particularly proliferating normal cells such as blood cells, epithelial cells, and cells lining the intestinal lumen. Such non-specific killing by chemotherapeutic agents results in side effects that are, at best, unpleasant, and can often result in unacceptable patient morbidity, or mortality. In fact, the undesirable side effects associated with cancer therapies often limit the treatment a patient can receive.

For other pathological conditions associated with abnormal angiogenesis such as diabetic retinopathy, there are no effective treatments short of retinal transplants. However, even if retinal transplantation is performed, the new retina would be subject to the same conditions that resulted in the original retinopathy. Thus, there exists a need to identify the molecular interactions involved in the undesirable angiogenesis that occurs in certain pathological conditions such that methods for diagnosing and specifically treating such pathologies can be developed. The present invention satisfies this need and provides related advantages as well.

### SUMMARY OF THE INVENTION

The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting  $\alpha 5\beta 1$  integrin associated with blood vessels in the tissue with an agent that interferes with specific binding of the  $\alpha 5\beta 1$  integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue. In one embodiment, the agent is an  $\alpha 5\beta 1$  antagonist that does not substantially interfere with the specific binding of an integrin other than  $\alpha 5\beta 1$  integrin to its ligand, for example,  $\alpha V\beta 3$  integrin binding to vitronectin. In another embodiment, the  $\alpha 5\beta 1$  integrin ligand is fibronectin.

A method of the invention is useful, for example, for reducing or inhibiting angiogenesis in ocular tissue such as retina, macula or cornea; in skin; in synovial tissue; in intestinal tissue; or in bone. In addition, a method of the invention is useful for reducing or inhibiting angiogenesis in a neoplasm, which can be benign or malignant and, where malignant, can be a metastatic neoplasm. As such, the invention provides medicaments, which contain  $\alpha 5\beta 1$  antagonists and are useful for reducing or inhibiting angiogenesis in an individual. An agent useful in practicing a method of the invention can be a peptide, for example, a peptide containing the amino acid sequence CRRETAWAC (SEQ ID NO: 1); an antibody, for example, an anti- $\alpha 5\beta 1$  integrin antibody or an  $\alpha 5\beta 1$  integrin binding fragment thereof; or a nonpeptide, small organic molecule, for example, (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxy-2,7-diazaspiro{4,4}-non-2-en-3-yl]carbonylamino} propionic acid. An agent useful as an  $\alpha 5\beta 1$  antagonist can be linked to a cytotoxin, for example, a cancer chemotherapeutic drug.

5 The invention also provides methods of  
identifying the presence of angiogenesis in a tissue by  
contacting the tissue with an agent that specifically  
binds  $\alpha 5\beta 1$  integrin, and detecting specific binding of the  
10 agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in  
the tissue. The agent can be a peptide, an antibody, or a  
nonpeptide, small organic molecule, and can be linked to a  
detectable label, which can be detected directly, or the  
presence of which can be detected due to its interaction  
15 with a particular reagent. Such a method is useful for  
identifying the presence of angiogenesis in various  
tissues, including in normal tissues such as embryonic  
tissue or placental tissue, in granulation tissue, or in a  
tissue involved in a pathological condition such as a  
20 neoplasm, a retinopathy, or an arthritic condition or  
other inflammatory condition.

25 The invention further provides methods of  
diagnosing a pathological condition characterized by  
angiogenesis in a tissue in an individual. A method of  
diagnosis can be performed, for example, by obtaining a  
sample of the tissue from the individual, wherein, in an  
individual having the pathological condition, the tissue  
exhibits angiogenesis; contacting the sample with an agent  
that specifically binds  $\alpha 5\beta 1$  integrin; and detecting  
30 specific binding of the agent to  $\alpha 5\beta 1$  integrin associated  
with a blood vessel in the tissue, thereby diagnosing a  
pathological condition characterized by angiogenesis in  
the individual. The pathological condition can involve  
the eye, for example, diabetic retinopathy or macular  
degeneration; the skin, for example, a hemangioma or  
psoriasis; a joint, for example, rheumatoid arthritis or  
osteoarthritis; or the intestine, for example Crohn's  
disease or ulcerative colitis; or can be a neoplasm, which  
can be benign or malignant. A malignant neoplasm, which  
35 can be metastatic, can be, for example, a breast



carcinoma, colon carcinoma, ovarian carcinoma, or pancreatic carcinoma.

A method of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual  
5 also can be performed by administering an agent that specifically binds  $\alpha 5\beta 1$  integrin to an individual suspected of having the pathological condition; and detecting specific binding of the agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in the tissue. The agent  
10 can be detectably labeled, for example, by linking it to a moiety such as a radionuclide, a paramagnetic material or an X-ray attenuating material. The method of detecting can be an *in vivo* imaging method such as a radionuclide imaging, positron emission tomography, computerized axial  
15 tomography, or magnetic resonance imaging method, or can be an *ex vivo* method, wherein, following administration of the agent, a sample of the tissue is obtained from the individual, and specific binding of the agent in the sample is detected. Agent that is specifically bound to  
20  $\alpha 5\beta 1$  integrin in such a sample can be detected directly, for example, by detecting radioactivity due to the moiety linked to the agent, or can be detected indirectly by contacting the specifically bound agent with a reagent that specifically interacts with the agent, or with the  
25 moiety, and detecting an interaction of the reagent with the agent or the moiety.

The present invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent  
30 that interferes with the specific binding of  $\alpha 5\beta 1$  integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue in the individual. Also provided is a method of reducing the severity of a pathological condition associated with angiogenesis in an

individual, by administering to the individual an agent that interferes with specific binding of  $\alpha 5 \beta 1$  integrin to a ligand in a tissue associated with the pathological condition, thereby reducing or inhibiting angiogenesis in the tissue and, consequently, reducing the severity of the pathological condition. The condition can be any pathological condition associated with angiogenesis, including a neoplasm, which can be a malignant neoplasm, for example, a carcinoma such as breast carcinoma, colon carcinoma, ovarian carcinoma or pancreatic carcinoma, or a sarcoma, mesothelioma, teratocarcinoma, an astrocytoma, glioblastoma, or other neoplasm, including a metastatic malignant neoplasm. The agent can be administered by various routes, for example, intravenously, orally, or directly into the region to be treated, for example, directly into a neoplastic tumor; via eye drops, where the pathological condition involves the eye; or intrasynovially, where the condition involves a joint.

The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with  $\alpha 5 \beta 1$  integrin expression in a tissue. Such a method, which is useful as a screening assay, can be performed by contacting a tissue exhibiting angiogenesis associated with  $\alpha 5 \beta 1$  integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue. Contacting of the tissue with the agent can occur *in vivo* or *ex vivo*. Where the method is performed using an *in vitro* format, it readily can be adapted for automated, high throughput screening assays. The tissue can be any tissue that undergoes angiogenesis associated with  $\alpha 5 \beta 1$  integrin expression, for example, malignant neoplastic tissue, and can be from any individual, including, for example, from a mammal, bird, reptile or amphibian.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 demonstrates the inhibitory effect of the nonpeptide small organic molecule, SJ749, on  $\alpha 5^+$  HT29 tumor cell adhesion to fibronectin.  $\alpha 5^+$  HT29 tumor cells were produced by transfecting HT29 cells with  $\alpha 5^+$  cDNA.

Figure 2 demonstrates the dose dependent inhibitory effect of SJ749 on blood vessel branch point formation in chorioallantoic membranes (CAM's). Angiogenesis was stimulated by treatment of the CAM's with basic fibroblast growth factor.

### **DETAILED DESCRIPTION OF THE INVENTION**

The present invention provides methods for detecting angiogenesis in a tissue by identifying  $\alpha 5\beta 1$  binding to a ligand in a blood vessel in the tissue.

15 Methods of diagnosing the presence of angiogenesis in an individual also are provided. The invention further provides methods for reducing or inhibiting angiogenesis in a tissue by interfering with the specific binding of  $\alpha 5\beta 1$  integrin to a ligand expressed in the tissue.

20 Methods of reducing or inhibiting angiogenesis, which can be associated with a pathological condition, in an individual, also are provided.

Angiogenesis depends on the cooperation of various growth factors and cell adhesion events. The  $\alpha V$  integrins have been shown to play critical roles in angiogenesis, although studies using  $\alpha V$  integrin null mice have suggested that other adhesion receptors and their ligands also may be involved in angiogenesis. As disclosed herein, the integrin  $\alpha 5\beta 1$  and its ligand fibronectin are coordinately upregulated during growth

factor stimulated angiogenesis and on blood vessels present in human tumor biopsies, and the interaction of these molecules is required for the angiogenesis that occurs during and supports tumor growth *in vivo*, as well  
5 as angiogenesis associated with various pathological conditions.

The development of vascular networks during embryogenesis or normal and pathological angiogenesis depends on stimulation induced by growth factors (Breier  
10 and Risau, Trends in Cell Biology 6:454-456 (1996); Breier et al., Thromb. Haemost. 78:678-683 (1997); Folkman, Nature Med. 1:27-31 (1995); Risau, Nature 386:671-674 (1997)) and on cellular interactions with the extracellular matrix (Stromblad and Cheresch, Chemistry and  
15 Biology 3:881-885 (1996); Varner, Exs. 79:361-390 (1997); each of the publications cited in this disclosure is incorporated herein by reference). Genetic and functional analyses indicate that extracellular components and cell surface receptors regulate endothelial cell growth,  
20 survival and differentiation in vasculogenesis and in angiogenesis (George et al., Development 119:1079-1091 (1993); Yang et al., Development 119:1093-1105 (1993); Stromblad and Cheresch, *supra*, 1996; Bloch et al., J. Cell Biol. 139: 265-278 (1997); Varner, *supra*, 1997; Risau,  
25 *supra*, 1997; Bader et al., Cell 95:507-519 (1998)).

Blood vessels arise during embryogenesis by two processes, vasculogenesis and angiogenesis (Risau, *supra*, 1997), and the role of growth factors in both processes is well established. For example, vascular endothelial  
30 growth factor (VEGF; Ferrara et al., Nature 380:439-442 (1996)) and its receptors (de Vries et al., Science 255:989-991 (1992); Fong et al., Nature 376:66-70 (1995); Millauer et al., Cell 72:835-846 (1993); Shalaby et al., Cell 89:981-990 (1997)), and basic fibroblast growth

factor (bFGF; Basilico and Moscatelli, Adv. Cancer Res. 59:115-165 (1992)) promote the initial development of the embryonic vascular network, and are involved in the formation of new blood vessels from pre-existing vessels during development, wound healing and the female reproductive cycle. VEGF (Warren et al., J. Clin. Invest. 95:1789-1797 (1995); Yoshida et al., Mol. Cell. Biol. 17:14015-4023 (1997); Kong et al., Human Gene Ther. 9:823-833 (1998)), bFGF (Stan et al., J. Neurosurg. 82:1044-1052 (1995); Chopra et al., J. Canc. Res. Clin. Oncol. 123:167-172 (1997); Czubyko et al., Nature Med. 3:1137-1140 (1997); Yoshida et. al., *supra*, 1997), Interleukin-8 (IL-8; Arenberg et al., J. Clin. Invest. 97:2792-2802 (1996); Luca et al., Am. J. Path. 151:1105-1113 (1997); Keane et al., J. Immunol. 159:1437-43 (1997); Yatsunami et al., Cancer Lett. 120:101-108 (1997); Yoshida et al., Invest. Ophthamol. Vis. Sci. 39:1097-1106 (1998)), and tumor necrosis factor- $\alpha$  (TNF $\alpha$ ; Yoshida et. al., *supra*, 1997) are some of the growth factors that have a role in the angiogenesis that is associated with various pathological conditions, including, for example, solid tumor growth, diabetic retinopathy, and rheumatoid arthritis.

While growth factors stimulate new blood vessel growth, adhesion to the extracellular matrix (ECM) regulates endothelial cell survival, proliferation and motility during new blood vessel growth (Stromblad and Cheresh, *supra*, 1996; Varner, *supra*, 1997). Specific integrins or their ligands also influence vascular development and angiogenesis. For example, the  $\alpha$ V integrins participate in angiogenesis by providing survival signals to activated endothelial cells (Arap et al., Science 279:377-380 (1997); Brooks et al., Science 264: 569-571 (1994a); Carron et al., Cancer Res. 58:1930-1955 (1998); Clark et al., Amer. J. Pathol. 148:1407-1421

(1997); Drake et al., Devel. Dyn. 193:83-91 (1992); Clark et al., J. Cell Science 108:2655-2661 (1995); Friedlander et al., Science 270:1500-1502 (1995)). However, some aspects of angiogenesis also can proceed in the absence of  
5  $\alpha$ V integrins (Bader et al., *supra*, 1998), suggesting that other molecules, including the  $\beta$ 1 integrin family, may compensate for the absence  $\alpha$ V integrins during development (Drake et al., *supra*, 1992; Bloch et al., *supra*, 1997; Senger et al., Proc. Natl. Acad. Sci., USA 94:13612-13617  
10 (1997)).

While active roles for integrins in the promotion of angiogenesis have been identified, the cognate ECM ligands for integrins that are involved in angiogenesis *in vivo* are less well described. One ECM  
15 protein, fibronectin, is expressed in provisional vascular matrices and provides proliferative signals to vascular cells during wound healing, atherosclerosis, and hypertension (Magnusson and Mosher, Arterioscler. Thromb. Vasc. Biol. 18:1363-1370 (1998)). Fibronectin expression  
20 is upregulated on blood vessels in granulation tissues during wound healing (Clark et al., J. Invest. Dermatol. 79:269-276 (1982)), and an isoform of fibronectin, the ED-B splice variant, is preferentially expressed on blood vessels in fetal and tumor tissues, but not on normal  
25 quiescent adult blood vessels (Castellani et al., Int. J. Cancer 59:612-618 (1994); Kaczmarek et al., Int. J. Cancer 58:11-16 (1994); Neri et al., Nature Biotech. 15:1271-1275 (1997)). These observations suggest that fibronectin may have a role in angiogenesis. In addition, animals that  
30 lack fibronectin die early in development from a collection of defects, including missing notochord and somites as well as an improperly formed vasculature (George et al., *supra*, 1993). Prior to the present disclosure, however, a direct functional role for

fibronectin in vasculogenesis or in angiogenesis was not established.

Several integrins bind to fibronectin (Hynes, Cell 69:11-25 (1992)), and integrin  $\alpha 5 \beta 1$  generally is selective for fibronectin (Pytela et al., Cell 40:191-98 (1985)). Studies have demonstrated that loss of the gene encoding the integrin  $\alpha 5$  subunit is embryonic lethal in mice and is associated with a complete absence of the posterior somites and with some vascular and cardiac defects (Yang et al., *supra*, 1993; Goh et al., Development 124: 4309-4319 (1997)). It was unclear, however, whether integrin  $\alpha 5 \beta 1$  has a direct role in the regulation of vascular development or of angiogenesis in particular.

As disclosed herein, both fibronectin and its receptor,  $\alpha 5 \beta 1$  integrin, directly regulate angiogenesis. Moreover, the specific interaction of fibronectin and  $\alpha 5 \beta 1$  is central to the contribution of these two molecules to angiogenesis. Integrin  $\alpha 5 \beta 1$  participates in pathways of angiogenesis that are the same as those of integrin  $\alpha V \beta 3$ , but distinct from the pathways involving  $\alpha V \beta 5$ . It is further disclosed herein that agents that interfere with the specific binding of  $\alpha 5 \beta 1$  and fibronectin can reduce or inhibit growth factor stimulated angiogenesis and the angiogenesis that occurs in tumors and, therefore, can be useful for treating various pathological conditions, including malignant neoplasms.

The participation of the central cell binding domain of fibronectin and its receptor  $\alpha 5 \beta 1$  in angiogenesis is disclosed herein. Expression of both integrin  $\alpha 5 \beta 1$  and fibronectin were significantly enhanced on blood vessels of human tumors and in growth factor stimulated tissues, while these molecules were minimally expressed on normal human vessels and on unstimulated tissues (Example I). In addition, antibody antagonists,

which bind the central cell binding domain of fibronectin and anti-  $\alpha 5 \beta 1$  antibodies, as well as two other classes of  $\alpha 5 \beta 1$  antagonists (peptides and nonpeptide, small organic molecule antagonists) blocked growth factor stimulated angiogenesis in chick chorioallantoic membrane (CAM; Example II) and in human skin grown on SCID mice (Example III). Antagonists of integrin  $\alpha 5 \beta 1$  blocked bFGF,  $\text{TNF}\alpha$  and IL-8 stimulated angiogenesis, but had a minimal effect on VEGF-induced angiogenesis. Each of these  $\alpha 5 \beta 1$  antagonists inhibited tumor angiogenesis and resulted in tumor regression in animal model systems (Example IV). Antagonists of fibronectin function also blocked both bFGF and VEGF angiogenesis, suggesting that other fibronectin receptors are involved in VEGF-mediated angiogenesis.

The results disclosed herein demonstrate that the expression of integrin  $\alpha 5 \beta 1$  and fibronectin in angiogenesis is coordinated. When the expression of each molecule is minimal, as on unstimulated, quiescent blood vessels, antagonists of each molecule and addition of fibronectin to chick chorioallantoic membranes (CAM's) had little effect on angiogenesis. In contrast, after stimulation with growth factors,  $\alpha 5 \beta 1$  and fibronectin expression are enhanced and blood vessels become sensitive to agents that act as antagonists of either molecule, as well as to the effects of exogenously added fibronectin. VEGF stimulation does not increase  $\alpha 5 \beta 1$  expression, supporting the observation that VEGF angiogenesis is refractory to antagonists of  $\alpha 5 \beta 1$ . This result is substantiated by a report that *in vitro* expression of integrin  $\alpha 5 \beta 1$  on endothelial cells was upregulated in response to bFGF (Collo and Pepper, J. Cell Sci. 112:569-578 (1999)), and that VEGF failed to upregulate  $\alpha 5 \beta 1$  expression (Senger et al., Am. J. Pathol. 149:1-7 (1996); Senger et al., Proc. Natl. Acad. Sci., USA 94:13612-13617 (1997)). Thus, the functional roles of integrin  $\alpha 5 \beta 1$  and



fibronectin in angiogenesis likely are a direct consequence of their growth factor induced expression.

Antibodies directed against the central cell binding fragment of fibronectin, which contains the RGD integrin binding site, inhibited angiogenesis (Examples II and III). These antibodies likely interfere with the specific binding of  $\alpha 5 \beta 1$  integrin to fibronectin, and, consequently, with possible downstream signal transduction events *in vivo*. Stimulation of bFGF angiogenesis by fibronectin and its cell binding domain in an  $\alpha 5 \beta 1$ -dependent manner indicate that  $\alpha 5 \beta 1$  is the integrin receptor for fibronectin during angiogenesis. The absence of integrin  $\alpha 5 \beta 1$  expression in VEGF stimulated angiogenesis likely accounts for the failure of fibronectin to enhance VEGF angiogenesis, even though antibodies directed against the cell binding peptide of fibronectin blocked VEGF angiogenesis. The results disclosed herein are the first demonstration of a direct *in vivo* role for fibronectin in angiogenesis.

The results disclosed herein also are the first to clearly identify a role for an extracellular matrix protein in the promotion of angiogenesis. Although collagens have been suggested to have roles in vascular development, intact collagens do not support endothelial cell outgrowth, survival or proliferation (Ilan et al., J. Cell Sci. 111:3621-3631 (1998); Isik et al., J. Cell. Phys. 175:149-155 (1999)). In fact, inhibition of the collagen receptors integrins  $\alpha 2 \beta 1$  and  $\alpha 1 \beta 1$  prevented the formation of large blood vessels and promoted the formation of small vessels (Senger et al., *supra*, 1997). Those results suggest that  $\alpha 2 \beta 1$ ,  $\alpha 1 \beta 1$ , and their ligand, collagen, are involved in blood vessel maturation, rather than in the promotion of new blood vessel sprouts.

A functional role for integrin  $\alpha 5 \beta 1$  in angiogenesis was established by demonstrating that agents that antagonize  $\alpha 5 \beta 1$  binding to its ligand blocked angiogenesis induced by growth factors and angiogenesis in tumor fragments (Examples II, III and IV). Like  $\alpha 5 \beta 1$ ,  $\alpha V \beta 3$  can serve as a fibronectin receptor (Charo et al., J. Cell Biol. 111:2795-800 (1990)), although, as disclosed herein, endothelial cells use  $\alpha 5 \beta 1$  as the major fibronectin receptor when both integrins are expressed.

The expression of  $\alpha 5 \beta 1$  and  $\alpha V \beta 3$  is regulated by similar growth factors, and both integrins have a significant role in bFGF,  $TNF\alpha$ , IL-8 and tumor-induced angiogenesis, but not in VEGF-induced angiogenesis (see Examples; see, also, Brooks et al., *supra*, 1994a; Brooks et al., Cell 79:1157-1164 (1994b); Friedlander et al., *supra*, 1995). These two integrins likely influence the same angiogenesis pathways, since combinations of their antagonists in angiogenesis animal models were neither additive nor synergistic (see Example II).

Binding of integrins to extracellular matrix proteins promotes cell attachment, migration, invasion, survival and proliferation (Varner, *supra*, 1997), and antagonists of  $\alpha V \beta 3$  induce apoptosis of proliferating endothelial cells *in vitro* and *in vivo* (Brooks et al., *supra*, 1994b; Stromblad et al., *supra*, 1996). As disclosed herein,  $\alpha 5 \beta 1$  antagonists also induce apoptosis of growth factor stimulated endothelial cells *in vitro* and *in vivo*.

Antagonists of  $\alpha 5 \beta 1$  blocked tumor angiogenesis and growth (Example IV), similar to antagonists of integrin  $\alpha V \beta 3$  (Brooks et al., *supra*, 1994b, 1995). The tumor cell lines used for *in vivo* tumorigenicity and

angiogenesis studies (Example IV) were integrin  $\alpha 5 \beta 1$  negative, to discount any direct effect of the antagonists on the tumor cells, and remained  $\alpha 5 \beta 1$  negative through the course of their culture on CAM's. HT29 tumors express a variety of growth factors, including VEGF,  $\text{TNF}\alpha$ ,  $\text{TGF}\alpha$ ,  $\text{TGF}\beta$ , PDGF and IL-8; it is not known whether HT29 cells also express bFGF. VEGF is most commonly associated with the hypoxic core of the tumor, and is transcriptionally regulated by hypoxia, whereas bFGF and other factors are associated with the growing edge of the tumor (Shweiki, et. al., *supra*, 1992; Kumar et al., Oncol. Res. 10:301-311 (1998)). As observed for growth factor stimulated CAM's,  $\alpha 5 \beta 1$  antagonists did not impact large pre-existing vessels on the CAM that underlie the transplanted tumors. These results demonstrate that agents that interfere with specific binding of  $\alpha 5 \beta 1$  to its ligands, particularly fibronectin, can reduce or inhibit angiogenesis. The use of such agents, therefore, can provide a clinical benefit to individuals suffering from various pathological conditions, including to cancer patients.

As used herein, the term "integrin" refers to the extracellular receptors that are expressed in a wide variety of cells and bind to specific ligands in the extracellular matrix. The specific ligands bound by integrins can contain an arginine-glycine-aspartic acid tripeptide (Arg-Gly-Asp; RGD) or a leucine-aspartic acid-valine tripeptide, and include, for example, fibronectin, vitronectin, osteopontin, tenascin, and von Willebrand's factor. The integrins comprise a superfamily of heterodimers composed of an  $\alpha$  subunit and a  $\beta$  subunit. Numerous  $\alpha$  subunits, designated, for example,  $\alpha \text{V}$ ,  $\alpha 5$  and the like, and numerous  $\beta$  subunits, designated, for example,  $\beta 1$ ,  $\beta 2$ ,  $\beta 3$ ,  $\beta 5$  and the like, have been identified, and various combinations of these subunits are represented in the integrin superfamily, including  $\alpha 5 \beta 1$ ,  $\alpha \text{V} \beta 3$  and  $\alpha \text{V} \beta 5$ . The superfamily of integrins can be

subdivided into families, for example, as  $\alpha$ V-containing integrins, including  $\alpha$ V $\beta$ 3 and  $\alpha$ V $\beta$ 5, or the  $\beta$ 1-containing integrins, including  $\alpha$ 5 $\beta$ 1 and  $\alpha$ V $\beta$ 1. Integrins are expressed in a wide range of organisms, including

5 *C. elegans*, *Drosophila* sp., amphibians, reptiles, birds, and mammals, including humans.

As disclosed herein, antibody, peptide and nonpeptide small organic molecule antagonists of  $\alpha$ 5 $\beta$ 1 can interfere with the specific binding of  $\alpha$ 5 $\beta$ 1 integrin with

10 its ligands, particularly fibronectin, in vascular tissue, and can reduce or inhibit angiogenesis (see Examples II, III and IV). Such molecules that interfere with the specific binding of  $\alpha$ 5 $\beta$ 1 with its ligands are referred to herein generally as "agents," "agent antagonists" or

15 " $\alpha$ 5 $\beta$ 1 antagonists." As used herein, the term "specific binding" or "binds specifically," when used in reference to the interaction of two or more molecules, means that the molecules can associate with each other under *in vivo* conditions and *in vitro* when incubated under appropriate

20 conditions, which can mimic *in vivo* conditions. The terms "specifically interact" and "specific association" also are used to refer to molecules that specifically bind.

For purposes of the present invention, the molecules that specifically interact with each other

25 generally are a receptor-type molecule and its ligand, including, for example, an integrin and its particular ligand or ligands, or an antibody and its particular antigen or antigens. It is recognized, however, that other molecules, for example, an  $\alpha$  integrin subunit and a

30  $\beta$  integrin subunit also interact specifically to form an integrin heterodimer, as can an  $\alpha$ 5 $\beta$ 1 antagonist and an  $\alpha$ 5 $\beta$ 1 integrin. Methods for determining whether two molecules specifically interact are disclosed herein, and methods of determining binding affinity and specificity

are well known in the art (see, for example, Harlow and Lane, Antibodies: A laboratory manual (Cold Spring Harbor Laboratory Press, 1988); Friefelder, "Physical Biochemistry: Applications to biochemistry and molecular biology" (W.H. Freeman and Co. 1976)).

Antibodies, peptides and nonpeptide small organic molecule antagonists that interfere with the specific binding of  $\alpha 5\beta 1$  with fibronectin are exemplified (see Example II). As used herein, the term "interfere," when used in reference to the action of an agent antagonist on the specific interaction of a receptor and its ligand, means that the affinity of the interaction is decreased below the level of binding that occurs in the absence of the agent. The skilled artisan will recognize that the association of a receptor and its ligand is a dynamic relationship that occurs among a population of such molecules such that, at any particular time, a certain proportion of receptors and ligands will be in association. An agent that interferes with the specific interaction of a receptor and its ligand, therefore, reduces the relative number of such interactions occurring at a given time and, in some cases, can completely inhibit all such associations.

The term "antagonist" is used herein to mean an agent, which can be an antibody, a peptide or a nonpeptide small organic molecule, that can interfere with the specific interaction of a receptor and its ligand. An anti- $\alpha 5\beta 1$  integrin antibody, which can interfere with the binding of  $\alpha 5\beta 1$  with fibronectin, thereby reducing or inhibiting the association of  $\alpha 5\beta 1$  integrin with fibronectin, is an example of an  $\alpha 5\beta 1$  antagonist. An antagonist can act as a competitive inhibitor or a noncompetitive inhibitor of  $\alpha 5\beta 1$  binding to its ligand.

004050-05039

It can be difficult to distinguish whether an antagonist completely inhibits the association of a receptor with its ligand or reduces the association below the limit of detection of a particular assay. Thus, the term "interfere" is used broadly herein to encompass reducing or inhibiting the specific binding of a receptor and its ligand. Furthermore, an agent can interfere with the specific binding of a receptor and its ligand by various mechanism, including, for example, by binding to the ligand binding site, thereby interfering with ligand binding; by binding to a site other than the ligand binding site of the receptor, but sterically interfering with ligand binding to the receptor; by binding the receptor and causing a conformational or other change in the receptor, which interferes with binding of the ligand; or by other mechanisms. Similarly, the agent can bind to or otherwise interact with the ligand to interfere with its specifically interacting with the receptor. For purposes of the methods disclosed herein for interfering with the specific interaction of an  $\alpha 5\beta 1$  integrin and its ligand, an understanding of the mechanism by which the interfering occurs is not required and no mechanism of action is proposed.

An agent that acts as an antagonist for  $\alpha 5\beta 1$  integrin binding to its ligand can be an antibody, particularly an anti- $\alpha 5\beta 1$  antibody or an anti-fibronectin antibody. As used herein, the term "antibody" is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as antigen binding fragments of such antibodies. With regard to an anti-integrin antibody, particularly an anti- $\alpha 5\beta 1$  antibody, the term "antigen" means an integrin, particularly an  $\alpha 5\beta 1$  integrin protein, polypeptide, or peptide portion thereof, which may or may not include some or all of an RGD binding domain. An anti- $\alpha 5\beta 1$  antibody, or antigen binding fragment thereof, is characterized by having specific binding activity for

an  $\alpha 5\beta 1$  integrin of at least about  $1 \times 10^5 \text{ M}^{-1}$ , generally at least about  $1 \times 10^6 \text{ M}^{-1}$ , and particularly at least about  $1 \times 10^7 \text{ M}^{-1}$ . Fab,  $\text{F(ab')}_2$ , Fd or Fv fragments of an anti- $\alpha 5\beta 1$  antibody, which retain specific binding activity for the  $\alpha 5\beta 1$  integrin are included within the definition of an antibody.

The term "antibody" as used herein encompasses naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, single chain antibodies, chimeric, bifunctional and humanized antibodies, as well as antigen-binding fragments thereof. Such non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be produced recombinantly or can be obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and variable light chains as described by Huse et al., Science 246:1275-1281 (1989), which is incorporated herein by reference. These and other methods of making, for example, chimeric, humanized, CDR-grafted, single chain, and bifunctional antibodies are well known to those skilled in the art (Winter and Harris, Immunol. Today 14:243-246 (1993); Ward et al., Nature 341:544-546 (1989); Harlow and Lane, *supra*, 1988; Hilyard et al., Protein Engineering: A practical approach (IRL Press 1992); Borrabeck, Antibody Engineering, 2d ed. (Oxford University Press 1995); each of which is incorporated herein by reference).

Anti-integrin antibodies, including anti- $\alpha 5\beta 1$  antibodies, can be purchased from a commercial source, for example, Chemicon, Inc. (Temecula CA), or can be raised using as an immunogen a substantially purified full length integrin, which can be a human integrin, mouse integrin or other mammalian or nonmammalian integrin that is prepared from natural sources or produced recombinantly, or a peptide portion of an integrin, which can include a

portion of the RGD binding domain, for example, a synthetic peptide. A non-immunogenic peptide portion of an integrin such as a human  $\alpha 5 \beta 1$  can be made immunogenic by coupling the hapten to a carrier molecule such bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH), or by expressing the peptide portion as a fusion protein. Various other carrier molecules and methods for coupling a hapten to a carrier molecule are well known in the art and described, for example, by Harlow and Lane (*supra*, 1988).

10                    Particularly useful antibodies for performing a method of the invention are those that specifically bind to an  $\alpha 5 \beta 1$  integrin. Such antibodies are particularly useful where they bind  $\alpha 5 \beta 1$  with at least an order of magnitude greater affinity than they bind another  
15 integrin, for example,  $\alpha V \beta 3$  or  $\alpha V \beta 5$ . An anti-fibronectin antibody also can be useful in a method of the invention, particularly an anti-fibronectin antibody that interferes with binding of fibronectin to  $\alpha 5 \beta 1$  integrin, but not to  $\alpha V \beta 3$  or other integrins.

20                    As disclosed herein, an anti- $\alpha 5 \beta 1$  antibody was used to detect regions of growth factor stimulated angiogenesis, as occurs in a pathological condition (see Example I). The presence or amount of  $\alpha 5 \beta 1$  integrin expression can be identified, for example, in a tissue  
25 sample, which can be a histological section obtained from a tissue or organ of an individual suspected of having a pathology characterized, at least in part, by undesirable angiogenesis. The identification of the presence or level of an  $\alpha 5 \beta 1$  integrin expression in the sample can be made  
30 using well known immunoassay or immunohistochemical methods (Harlow and Lane, *supra*, 1988). An anti- $\alpha 5 \beta 1$  antibody, particularly an antibody that prevents ligand binding to the  $\alpha 5 \beta 1$  integrin, also can be used in a screening assay to identify agents that compete for ligand



binding to the integrin. As disclosed herein, such agents can be useful for inhibiting  $\alpha 5\beta 1$  mediated angiogenesis.

Peptides that specifically bind to  $\alpha 5\beta 1$  also are useful as antagonists of  $\alpha 5\beta 1$  binding to its ligands, including fibronectin. As discussed for anti- $\alpha 5\beta 1$  antibodies, a peptide that specifically binds  $\alpha 5\beta 1$  can be useful in a method of the invention where the antibody binds to  $\alpha 5\beta 1$  with at least about a two-fold greater specificity than it binds to another integrin, for example,  $\alpha V\beta 3$ , is more useful if it has at least about a five-fold greater specificity for  $\alpha 5\beta 1$ , and is particularly useful if it has at least about a one order of magnitude greater specificity for  $\alpha 5\beta 1$  than for an integrin such as  $\alpha V\beta 3$ . As such, the various RGD and RLD containing peptides that have been identified based on their relatively high binding affinity for  $\alpha V\beta 3$  or for  $\alpha V\beta 5$  (PCT/US94/13542) are not considered peptide antagonists of  $\alpha 5\beta 1$  binding to its ligand, as defined herein.

The term "peptide" is used broadly herein to include oligomers and polymers of amino acids or amino acid analogs that are linked by a peptide bond or an analog of a peptide bond. As such, the term "peptide" includes molecules commonly referred to as peptides, which generally contain about two to about fifty amino acids, as polypeptides, which generally contain about twenty to fifty amino acids or more, and as proteins, which can include peptides or polypeptides that, for example, are post-translationally modified. Thus, peptide antagonists contain two or more amino acids, which can be L-amino acids or D-amino acids, chemically modified amino acids, which can be naturally occurring or non-naturally occurring amino acids, or amino acid analogs. Peptides useful as  $\alpha 5\beta 1$  antagonists that reduce or inhibit angiogenesis can be identified by screening libraries of

peptides, which can be prepared using well known methods of chemical synthesis (see, for example, Koivunen et al., *supra* 1993, 1994), or can be purchased from commercial sources.

5           An agent that interferes with  $\alpha 5 \beta 1$  binding to its ligand also can be a nonpeptide, small organic molecule, including a peptidomimetic, which is an organic molecules that mimics the structure of a peptide; or a peptoid such as a vinylogous peptoid. A nonpeptide small  
10 organic molecule that acts as an antagonist to the specific interaction of  $\alpha 5 \beta 1$  integrin binding to a ligand, fibronectin, can be, for example, a heterocycle having the general structure (S)-2-phenylsulfonylamino-3-{{8-(2-pyridinyl aminomethyl)-}-1-oxa-2-azaspiro-{4,5}-dec-  
15 2-en-yl} carbonylamino} propionic acid, as exemplified herein by the molecule designated SJ749, which has the structure: (S)-2-{{(2,4,6-trimethylphenyl) sulfonyl} amino-3-{{7-benzyloxycarbonyl-8-(2-pyridinyl aminomethyl)-1-oxa-2,7-diazaspiro-{4,4}-non-2-en-3-yl} carbonylamino}  
20 propionic acid (see Examples II and IV; U.S. Patent No. 5,760,029). As disclosed herein, SJ749 interfered with  $\alpha 5 \beta 1$  binding to fibronectin and reduced or inhibited angiogenesis in a dose dependent manner (see Figure 2). Additional nonpeptide, small organic molecule  $\alpha 5 \beta 1$   
25 antagonists useful in a method of the invention can be identified by screening, for example, chemically modified derivatives of a heterocycle having the structure disclosed above, including chemically modified derivatives of SJ749, or other libraries of nonpeptide, small organic  
30 molecules (see below).

          The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting  $\alpha 5 \beta 1$  integrin in the tissue with an agent that interferes with specific binding of the  $\alpha 5 \beta 1$  integrin to a  
35 ligand expressed in the tissue, thereby reducing or

inhibiting angiogenesis in the tissue. A particularly useful agent antagonist interferes with the binding of  $\alpha 5 \beta 1$  to fibronectin, but does not substantially interfere with the specific binding of the ligand to an integrin other than  $\alpha 5 \beta 1$  integrin. As disclosed herein, an agent such as an anti- $\alpha 5 \beta 1$  antibody, a peptide, or a nonpeptide small organic molecule that interferes with binding of  $\alpha 5 \beta 1$  integrin to its ligand can reduce or inhibit growth factor stimulated angiogenesis and angiogenesis that occurs during tumor growth (see Examples II, III and IV).

As used herein, the phrase "reduce or inhibit," when used in reference to angiogenesis, means that the amount of new blood vessel formation that occurs in the presence of an agent antagonist is decreased below the amount of blood vessel formation that occurs in the absence of an exogenously added agent antagonist. The terms "reduce" and "inhibit" are used together because it is recognized that the amount of angiogenesis can be decreased below a level detectable by a particular assay method and, therefore, it may not be possible to determine whether angiogenesis is reduced to a very low level or completely inhibited. Nevertheless, it will be clear from the particular assay being used that, in response to an agent that interferes with  $\alpha 5 \beta 1$  integrin to its ligand, angiogenesis in a tissue is decreased below the level of angiogenesis in corresponding untreated tissue. Methods for determining an amount of blood vessel formation in a tissue, including the immunohistochemical methods disclosed herein (Example I), are well known in the art.

A method of the invention is useful, for example, for reducing or inhibiting angiogenesis in ocular tissue such as retina, macula or cornea; in skin such as occurs with psoriasis; in synovial tissue; in bone; or in intestinal tissue, by interfering with  $\alpha 5 \beta 1$  binding to a ligand such as fibronectin in the tissue. In addition, a

method of the invention is useful for reducing or inhibiting angiogenesis in a neoplasm, which can be benign or malignant and, where malignant, can be a metastatic neoplasm. An agent useful in practicing a method of the invention can be a peptide, for example, a peptide containing the amino acid sequence CRRETAWAC (SEQ ID NO: 1); an antibody, for example, an anti- $\alpha 5\beta 1$  integrin antibody or an  $\alpha 5\beta 1$  integrin binding fragment thereof; or a nonpeptide, small organic molecule, for example, (S)-2-((2,4,6-trimethylphenyl)sulfonyl)amino-3-(7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxy-2,7-diazaspiro-{4,4}-non-2-en-3-yl)carbonylamino propionic acid (SJ749). If desired, the agent can be linked to a cytotoxin such as ricin or a cancer chemotherapeutic drug, provided linkage of the cytotoxin does not substantially reduce the ability of the agent to specifically bind  $\alpha 5\beta 1$  integrin and interfere with the binding of  $\alpha 5\beta 1$  to its ligand.

The invention also provides methods of identifying the presence of angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds  $\alpha 5\beta 1$  integrin, and detecting specific binding of the agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in the tissue, thereby identifying the presence of angiogenesis in the tissue. The agent can be a peptide, an antibody, or a nonpeptide, small organic molecule, and can be linked to a detectable label, which can be detected directly, or the presence of which can be detected due to its interaction with a particular reagent. Such a method is useful for identifying the presence of angiogenesis in various tissues, including, for example, normal tissues such as embryonic tissue or placental tissue, granulation tissue, and a tissue involved in a pathological condition. As such, the invention further provides methods of diagnosing a pathological condition characterized by

angiogenesis associated with  $\alpha 5\beta 1$  integrin expression in a tissue in an individual.

The term "pathological condition" is used broadly herein to mean any abnormal physical or  
5 physiological condition characterized, at least in part, by angiogenesis associated with  $\alpha 5\beta 1$  integrin expression on newly forming blood vessels in a tissue. Such pathological conditions are exemplified by neoplasms (see Example I), ocular diseases such as diabetic retinopathy  
10 and macular degeneration associated with neovascularization, skin diseases such as psoriasis and hemangiomas, gingivitis, arthritic conditions such as rheumatoid arthritis and osteoarthritis, and inflammatory bowel diseases. Other pathological conditions amenable to  
15 a diagnostic or other method of the invention can be identified using methods such as those disclosed in Example I or otherwise known in the art.

The term "neoplasm" is used broadly herein to mean any new, pathological tissue growth. For purposes of  
20 the present invention, a neoplasm generally results in the formation of a tumor, which is characterized, in part, by angiogenesis. A neoplasm can be benign, for example, a hemangioma, glioma, teratoma, and the like, or can be malignant, for example, a carcinoma, sarcoma,  
25 glioblastoma, astrocytoma, neuroblastoma, retinoblastoma, and the like. The term "tumor" is used generally to refer to a benign or malignant neoplasm, and the term "cancer" is used generally to refer to a malignant neoplasm, which may or may not be metastatic. Malignant neoplasms that  
30 can be diagnosed using a method of the invention include, for example, carcinomas such as lung cancer, breast cancer, prostate cancer, cervical cancer, pancreatic cancer, colon cancer and ovarian cancer; and sarcomas such as osteosarcoma and Kaposi's sarcoma, provided the  
35 neoplasm is characterized, at least in part, by

angiogenesis associated with  $\alpha 5\beta 1$  expression by the newly forming blood vessels (see Examples I and III).

5 A method of diagnosis can be performed, for example, by obtaining a sample of the tissue from the individual, wherein, in an individual having the pathological condition, the tissue exhibits angiogenesis; contacting the sample with an agent that specifically binds  $\alpha 5\beta 1$  integrin; and detecting specific binding of the agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in  
10 the tissue. An individual to be diagnosed or treated using a method of the invention can be any individual exhibiting angiogenesis associated with  $\alpha 5\beta 1$  integrin expression and, therefore, can be, for example, a vertebrate such as a mammal, including a human, dog, cat,  
15 horse, cow, or goat; a bird; or any other animal, particularly a commercially important animal or a domesticated animal.

20 A method of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual also can be performed by administering an agent that specifically binds  $\alpha 5\beta 1$  integrin to an individual suspected of having the pathological condition; and detecting specific binding of the agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in the tissue. The agent  
25 can be detectably labeled, for example, by linking the agent to a moiety, which is selected based, for example, on whether specific binding of the agent is to be detected *in vivo* or whether a tissue to which the agent is suspected of binding is to be removed, for example, by  
30 biopsy, and examined *ex vivo*.

A moiety useful for labeling an agent antagonist can be a radionuclide, a paramagnetic material, an X-ray attenuating material, a fluorescent,

chemiluminescent or luminescent molecule, a molecule such as biotin, or a molecule that can be visualized upon reaction with a particular reagent, for example, a substrate for an enzyme or an epitope for an antibody.

- 5 The moiety can be linked to an agent using well known methods, which are selected, in part, based on the chemical nature of the agent and the moiety. For example, where the moiety is an amino acid sequence such as a hexahistidine (His6) sequence, and the agent is a peptide,
- 10 the His6 sequence can be synthesized as part of the peptide, and the His6-labeled agent can be identified by the binding of a nickel ion reagent to the His6 moiety. Methods for chemically linking a moiety to an agent also can be utilized (see, for example, Hermanson, Bioconjugate
- 15 Techniques, (Academic Press 1996), which is incorporated herein by reference).

- A specifically bound agent can be detected in an individual using an *in vivo* imaging method such as a radionuclide imaging, positron emission tomography,
- 20 computerized axial tomography, or magnetic resonance imaging method, or can be detected using an *ex vivo* method, wherein, following administration, a sample of the tissue is obtained from the individual, and specific binding of the agent in the sample is detected. An agent
- 25 that is specifically bound to  $\alpha 5\beta 1$  integrin in a sample can be detected directly, for example, by detecting the agent or by detecting the presence of a moiety such as by detecting radioactivity emitted by a radionuclide moiety. Specifically bound agent also can be detected indirectly
- 30 by further contacting it with a reagent that specifically interacts with the agent, or with a moiety linked to the agent, and detecting interaction of the reagent with the agent or label. For example, the moiety can be detected by contacting it with an antibody that specifically binds
- 35 the moiety, particularly when the moiety is linked to the

agent. The moiety also can be, for example, a substrate, which is contacted by an enzyme that interacts with and changes the moiety such that its presence can be detected. Such indirect detection systems, which include the use of  
5 enzymes such as alkaline phosphatase, horseradish peroxidase, beta-galactosidase and the like, are well known in the art and commercially available, as are the methods for incorporating or linking the particular moiety to a particular type of agent.

10           The present invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of  $\alpha 5 \beta 1$  integrin to a ligand expressed in the tissue, thereby reducing or  
15 inhibiting angiogenesis in the tissue in the individual. As such, the invention provides methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding  
20 of  $\alpha 5 \beta 1$  integrin to a ligand in a tissue associated with the pathological condition, thereby reducing or inhibiting angiogenesis in the tissue, and, consequently, reducing the severity of the pathological condition.

          As used herein, the term "reducing the severity  
25 of a pathological condition" means that adverse clinical signs or symptoms associated with the pathological condition are ameliorated. A reduction in the severity of a pathologic condition can be detected by various methods, including routine clinical tests such as blood tests,  
30 which can be used to determine relevant enzyme levels or circulating antigen or antibody; imaging tests, which can be used to detect a decrease in the growth rate or size of a neoplasm; or an ophthalmic procedure, which can be used to identify a reduction in the number of blood vessels in  
35 the retina of a diabetic patient. Such clinical tests are



selected based on the particular pathological condition being treated. A reduction in the severity of a pathological condition also can be detected based on comments made by the patient being treated, for example, 5 that a patient suffering from arthritis feels less pain or has greater joint mobility, or that a patient with diabetic retinopathy or with macular degeneration due to neovascularization can see more clearly, or the like.

Where an agent that interferes with the 10 specific binding of an  $\alpha 5 \beta 1$  integrin to its ligand is to be administered to a living individual, for example, for a diagnostic or therapeutic procedure, the agent generally will be in the form of a pharmaceutical compositions comprising the agent or agents and a pharmaceutically 15 acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include aqueous solutions such as physiologically buffered saline or other buffers or solvents or vehicles such as glycols, glycerol, oils such as olive oil or injectable organic esters. The 20 selection of a pharmaceutically acceptable carrier will depend, in part, on the chemical nature of the agent, for example, whether the agent is an antibody, a peptide or a nonpeptide, small organic molecule.

A pharmaceutically acceptable carrier can 25 physiologically acceptable compounds that act, for example, to stabilize the agent or increase its absorption, or other excipients as desired. Physiologically acceptable compounds include, for example, carbohydrates, such as glucose, sucrose or dextrans, 30 antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. One skilled in the art would know that the choice of a pharmaceutically acceptable carrier, including a physiologically acceptable compound, 35 depends, for example, on the route of administration of

the agent and on the particular physio-chemical characteristics of the agent.

Angiogenesis associated with  $\alpha 5 \beta 1$  integrin expression can occur locally, for example, in the retina of an individual suffering from diabetic retinopathy, or can occur more systemically, for example, in an individual suffering from rheumatoid arthritis or a metastatic malignant neoplasm. Since regions of such angiogenesis can be localized or can more systemically dispersed, one skilled in the art would select a particular route and method of administration of an agent that interferes with the specific binding of an  $\alpha 5 \beta 1$  integrin with its ligand, for example, fibronectin, based, in part, on this factor. For example, in an individual suffering from diabetic retinopathy, where angiogenesis associated with  $\alpha 5 \beta 1$  integrin expression is localized to the retina, the agent can be formulated in a pharmaceutical composition convenient for use as eye drops, which can be administered directly to the eye. In comparison, in an individual suffering from a metastatic carcinoma, the agent in a pharmaceutical composition that can be administered intravenously, orally or by another method that distributes the agent systemically. Thus, an agent antagonist can be administered by various routes, for example, intravenously, orally, or directly into the region to be treated, for example, directly into a neoplastic tumor; via eye drops, where the pathological condition involves the eye; or intrasynovially, where the condition involves a joint.

The amount of an  $\alpha 5 \beta 1$  agent antagonist that is administered to an individual will depend, in part, on whether the agent is administered for a diagnostic purpose or for a therapeutic purpose. Methods for determining an effective amount of an agent to administer for a diagnostic or a therapeutic procedure are well known in

the art and include phase I, phase II and phase III clinical trials. An agent is administered in an effective amount, which is an amount sufficient to interfere with the specific binding of  $\alpha 5 \beta 1$  integrin to its specific  
5 ligand in an individual. Generally, an agent antagonist is administered in a dose of about 0.0001 to 100 mg/kg body weight.

As disclosed herein, systemic administration of  
5  $\mu$ g anti- $\alpha 5 \beta 1$  antibody/2 ml blood volume of chick embryo  
10 inhibited 50% of the growth factor stimulated angiogenesis (Example II). Similarly, administration of 120 picomoles of CRRETAWAC (SEQ ID NO: 1)/2 ml blood volume, and administration of 15 picomoles of SJ749/2 ml blood volume inhibited angiogenesis by 50%. Based on these results,  
15 the skilled artisan can estimate the amounts of such agents required to effectively inhibit angiogenesis in a tissue in an individual such as a human, and routine clinical trials can be used to determine optimal dosages. Assuming, for example, that a human has a blood volume of  
20 about six liters, the artisan would know that a range of amounts less than or around about 15 milligrams of an anti- $\alpha 5 \beta 1$  antibody can be used in a clinical trial for determining an amount of the agent to be administered to a human. Estimates of an amount to be administered can be  
25 adjusted accordingly, for example, where the agent is to be administered locally.

The total amount of an agent antagonist can be administered to a subject as a single dose, either as a bolus or by infusion over a relatively short period of  
30 time, or can be administered using a fractionated treatment protocol, in which the multiple doses are administered over a more prolonged period of time. One skilled in the art would know that the concentration of a particular agent required to provide an effective amount  
35 to a region or regions of angiogenesis associated with

α5β1 integrin expression in an individual depends on many factors including the age and general health of the subject as well as the route of administration, the number of treatments to be administered, and the nature of the agent, including whether the agent is an antibody, a peptide, or a non-peptide small organic molecule. In view of these factors, the skilled artisan would adjust the particular dose so as to obtain an effective amount for efficaciously interfering with the specific binding of α5β1 integrin with its ligand, thereby allowing either for detection of the agent at a region of angiogenesis associated with α5β1 integrin expression for diagnostic purposes, or for reducing or inhibiting such angiogenesis for therapeutic purposes.

15           An agent useful for detecting or reducing or inhibiting angiogenesis associated with α5β1 integrin expression, or a pharmaceutical composition thereof containing the agent, can be used for treating any pathological condition that is characterized, at least in part, by such angiogenesis. One skilled in the art would know that the agent can be administered by various routes including, for example, orally, or parenterally, including intravenously, intramuscularly, subcutaneously, intraorbitally, intracapsularly, intrasynovially, intraperitoneally, intracisternally or by passive or facilitated absorption through the skin using, for example, a skin patch or transdermal iontophoresis. Furthermore, the agent can be administered by injection, intubation, via a suppository, orally or topically, the latter of which can be passive, for example, by direct application of an ointment or powder containing the agent, or active, for example, using a nasal spray or inhalant. The agent can also be administered as a topical spray, if desired, in which case one component of the composition is an appropriate propellant. The pharmaceutical composition also can be incorporated, if desired, into liposomes,

microspheres or other polymer matrices (Gregoriadis, Liposome Technology, Vol. 1 (CRC Press, Boca Raton, FL 1984), which is incorporated herein by reference).

Liposomes, for example, which consist of phospholipids or  
5 other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

As disclosed herein, agents that interfere with  
 $\alpha 5 \beta 1$  integrin binding to its ligand can reduce or inhibit  
10 angiogenesis associated with  $\alpha 5 \beta 1$  expression. In addition to the exemplified agent antagonists, other such agents can be identified by detecting agents that interfere  $\alpha 5 \beta 1$  integrin binding to its ligand. Thus, the invention provides screening assays, which are useful for  
15 identifying an agent that reduces or inhibits angiogenesis associated with  $\alpha 5 \beta 1$  integrin expression in a tissue.

A screening assay of the invention can be performed by contacting a tissue exhibiting angiogenesis associated with  $\alpha 5 \beta 1$  integrin expression with an agent,  
20 and detecting a reduction or inhibition of angiogenesis in the tissue, thereby identifying an agent that reduces or inhibits angiogenesis associated with  $\alpha 5 \beta 1$  integrin expression in a tissue. A tissue can be contacted with the agent *in vivo* or *ex vivo* (see, for example, U.S.  
25 Patent No. 5,622,699). Where a screening method of the invention is performed using an *in vitro* format, the can be adapted to automated procedure, thus allowing high throughput screening assays for examining libraries of molecules to identify potential  $\alpha 5 \beta 1$  antagonists, which  
30 can reduce or inhibit angiogenesis associated with  $\alpha 5 \beta 1$  expression. The tissue can be any tissue that undergoes angiogenesis associated with  $\alpha 5 \beta 1$  integrin expression, for example, malignant neoplastic tissue.

Methods for preparing libraries of molecules, which can be screened using a method of the invention to identify  $\alpha 5 \beta 1$  antagonists, which reduce or inhibit angiogenesis associated with  $\alpha 5 \beta 1$  expression, including, 5 for example, oligonucleotide libraries (Gold et al., U.S. Patent No.: 5,270,163); peptide libraries (Koivunen et al., *supra*, 1993, 1994); peptidomimetic libraries (Blondelle et al., Trends Anal. Chem., 14:83-92 (1995)); oligosaccharide libraries (York et al., Carb. Res., 10 285:99-128, (1996); Liang et al., Science, 274:1520-1522, (1996); and Ding et al., Adv. Expt. Med. Biol., 376:261-269, (1995)); lipoprotein libraries (de Kruif et al., FEBS Lett., 399:232-236, (1996)); glycoprotein or glycolipid libraries (Karaoglu et al., J. Cell Biol., 15 130:567-577 (1995)); or chemical libraries containing, for example, drugs or other pharmaceutical agents (Gordon et al., J. Med. Chem., 37:1385-1401 (1994); Ecker and Crook, Bio/Technology, 13:351-360 (1995)), including, for example, heterocycles having the general 20 structure (S)-2-phenylsulfonylamino-3-{{8-(2-pyridinyl aminomethyl)-}-1-oxa-2-azaspiro-{4,5}-dec-2-en-yl} carbonylamino} propionic acid (U.S. Patent No. 5,760,029). Libraries of diverse molecules also can be obtained from commercial sources.

25           The following examples are intended to illustrate but not limit the present invention.

#### EXAMPLE I

##### $\alpha 5 \beta 1$ INTEGRIN IS EXPRESSED DURING ANGIOGENESIS

This Example provides immunohistochemical 30 evidence that  $\alpha 5 \beta 1$  is expressed in association with newly formed blood vessels in various human and mouse tumors.

Five  $\mu\text{m}$  frozen sections of human normal breast and colon, colon carcinoma, breast carcinoma, human tumor xenotransplants in six week old CB17 female SCID mice (Charles River; Wilmington MA), and in breast tumors from 5 Mtag mice were fixed for 1 min in acetone, air dried and rehydrated for 5 min in phosphate buffered saline (PBS). Sections were blocked for 2 hr in 8% normal goat serum in PBS and incubated with: 1) 5  $\mu\text{g}/\text{ml}$  anti- $\alpha 5\beta 1$  cytoplasmic tail polyclonal antibody (AB1928P; Pharmingen, Inc.; San 10 Diego CA) and 5  $\mu\text{g}/\text{ml}$  murine anti-human CD31 monoclonal antibody (PECAM; MA-3100; Endogen); 2) 5  $\mu\text{g}/\text{ml}$  anti- $\alpha 5\beta 1$  monoclonal antibody and 5  $\mu\text{g}/\text{ml}$  rabbit anti-von Willebrand's factor antibody (016P; Biogenex; San Ramon CA); or 3) 5  $\mu\text{g}/\text{ml}$  anti-fibronectin cell binding peptide 15 monoclonal antibody (784A2A6; Chemicon, Inc.; Temecula CA) and 5  $\mu\text{g}/\text{ml}$  anti-von Willebrand's factor antibody (016P), in 2% bovine serum albumin (BSA) in PBS for 2 hr at room temperature (RT).

Sections were washed by dipping in six fresh 20 changes of PBS and incubated in 1:400-1:600 dilutions of goat anti-rabbit-FITC and in 1:400-1:600 goat anti-mouse-rhodamine for 1 hr at RT (cross-absorbed secondary antibodies; Biosource International; Camarillo CA). Slides were washed, and coverslips were mounted in one 25 drop of Fluoromount-G (Southern Biotechnology Associates; Birmingham AL) prior to digital image analysis under fluorescent illumination using a supercooled CCD camera.

Analysis of frozen sections of human colon carcinoma and breast carcinoma for expression of the 30 endothelial cell marker CD31 (PECAM) and integrin  $\alpha 5\beta 1$  by two color immunohistochemistry indicated that CD31 positive tumor vessels (stained red) also were positive for integrin  $\alpha 5\beta 1$  expression (stained green); vessels positive for both molecules appeared yellow by 35 photomicrography. Large vessels with lumens, as well as

large and small vessels without apparent lumens stained positively for integrin  $\alpha 5\beta 1$  and CD31. Sections of ovarian and pancreatic carcinoma showed similar patterns of integrin  $\alpha 5\beta 1$  expression on blood vessels. In

5 contrast, CD31 positive blood vessels present in sections of normal human colon and breast were negative for integrin  $\alpha 5\beta 1$ , as were blood vessels in other normal adult tissues, including skin. These results demonstrate that integrin  $\alpha 5\beta 1$  expression is upregulated on tumor  
10 vasculature and that the majority of blood vessels in these tumor sections are positive for  $\alpha 5\beta 1$  expression. The results further demonstrate that  $\alpha 5\beta 1$  is not significantly expressed on blood vessels in normal adult tissues.

15 Tumor tissues also were stained with antibodies directed against fibronectin (stained red) and von Willebrand's Factor (stained green), which is another blood vessel marker. Examination of frozen sections of breast carcinoma and colon carcinoma, as well as normal  
20 human breast and colon indicated that the extracellular matrix surrounding tumor vessels was positive for fibronectin expression. In contrast, blood vessels in normal tissues expressed little, if any, fibronectin. Sections of ovarian and pancreatic carcinoma showed  
25 similar patterns of fibronectin expression on blood vessels.

Notably, the expression of integrin  $\alpha 5\beta 1$  and its ligand, fibronectin, were coordinately upregulated on  
30 sections. These coordinate expression of these molecules in human tumor tissues is indicative of a possible functional interaction between these proteins. Expression of integrin  $\alpha 5\beta 1$  and fibronectin also were observed on tumor vasculature in animal models of neoplasia, including  
35 human M21L melanoma tumor xenotransplants in SCID mice and



spontaneous mammary tumors in the PyV mouse (see Guy et al., Mol. Cell Biol. 12:954-961 (1992), which is incorporated herein by reference, regarding PyV mouse model). Thus, significantly elevated expression of  
5 integrin  $\alpha 5 \beta 1$  and fibronectin is associated with the vasculature in spontaneous tumors and in experimentally induced human and murine tumors compared to normal tissues.

## EXAMPLE II

### 10 $\alpha 5 \beta 1$ AND FIBRONECTIN ARE REQUIRED FOR ANGIOGENESIS

This example demonstrates that fibronectin and the fibronectin receptor integrin  $\alpha 5 \beta 1$  are involved in angiogenesis in tumors and in growth factor stimulated angiogenesis.

#### 15 A. METHODS

##### 1. Cell Adhesion Assay

HT29 integrin  $\alpha 5 \beta 1^+$  cells, integrin  $\alpha 5 \beta 1^-$  colon carcinoma cells (Varner et al., Mol. Biol. Cell 6:725-740 (1995)), and chick embryo fibroblasts (CEF's) were  
20 maintained in DMEM high glucose supplemented with 10% fetal bovine serum (FBS) and gentamycin. Human umbilical vein endothelial cells (HUVEC's) were maintained in M199 medium containing sodium bicarbonate, HEPES, heparin, endothelial cell growth supplement, 20% FBS and  
25 gentamycin. Culture media and reagents were from Irvine Scientific (Irvine, CA).

The wells of 48 well culture dishes (Costar, Inc.) were coated with 1  $\mu$ g/ml vitronectin, 2  $\mu$ g/ml fibronectin (chick embryo fibroblasts and HUVEC's) or  
30 10  $\mu$ g/ml fibronectin (HT29- $\alpha 5^+$  cells) for 1 hr at 37°C, then blocked with 2% heat denatured BSA in PBS for 1 hr. Fifty thousand cells in 250  $\mu$ l of adhesion buffer were

added to triplicate wells containing 250  $\mu$ l of a solution of 50  $\mu$ g/ml of an anti- $\alpha$ 5 $\beta$ 1 function blocking antibody (NKI-SAM-1, JBS5 or IIA1), 50  $\mu$ g/ml of an anti- $\alpha$ 5 $\beta$ 1 non-function blocking antibody (HA5 or VC5; Pharmingen, Inc.; San Diego CA), 10  $\mu$ M cyclic peptides (Koivunen et al., *J. Biol. Chem.* 268:20205-20210 (1993); Koivunen et al., *J. Cell Biol.* 124:373380 (1994)), 0-10  $\mu$ M SJ749 ((S)-2-((2,4,6-trimethylphenyl) sulfonyl) amino-3-{7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-{4,4}-non-2-en-3-yl} carbonylamino} propionic acid)), 50  $\mu$ g/ml of LM609, an anti- $\alpha$ V $\beta$ 3 function blocking antibody, 50  $\mu$ g/ml P4C10, an anti- $\beta$ 1 function blocking antibody, 50  $\mu$ g/ml of an anti-fibronectin cell binding domain monoclonal antibody or 50  $\mu$ g/ml of an anti-fibronectin N-terminus monoclonal antibody in adhesion buffer (HEPES buffered Hanks balanced salt solution, HBSS, containing 1% BSA, 2 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub> and 0.2 mM MnCl<sub>2</sub>).

Cells were allowed to adhere to dishes for 20 min at 37°C. Nonadherent cells were removed by washing each well four times with 500  $\mu$ l of warm adhesion buffer. Adherent cells were then fixed for 15 min with 3.7% paraformaldehyde in PBS and stained with a 2% crystal violet solution. After extensive water washing to remove excess crystal violet, plates were dried overnight. Crystal violet was extracted by incubation for 15 min in 10% acetic acid and absorbance at 562 nm determined as an indicator of number of cells bound. Each experiment was performed in triplicate, with triplicate samples per condition. Data was presented as percent of adhesion exhibited by the positive control (adhesion medium alone) +/- standard error of measurement.

## 2. Cell Migration Assays

The lower side of 8  $\mu$ m pore transwell inserts (Costar, Inc.) were coated with 2  $\mu$ g/ml of fibronectin,

collagen (Collaborative Biomedical Products; Bedford MA) or no protein for 1 hr and were blocked with 2% BSA in PBS for 1 hr. The inserts then were placed into 24 well culture dishes containing 500  $\mu$ l migration buffer in the lower chamber. Twenty-five thousand HUVEC's in 50  $\mu$ l of migration buffer (HEPES buffered M199 medium containing 1% BSA, 2 mM  $MgCl_2$ , 2 mM  $CaCl_2$  and 0.2 mM  $MnCl_2$ ) were added to the upper chamber of duplicate inserts containing 50  $\mu$ l of a solution of 50  $\mu$ g/ml of anti- $\alpha 5\beta 1$  function blocking antibody (NKI-SAM-1, JBS5 or IIA1), 50  $\mu$ g/ml of anti- $\alpha 5\beta 1$  non-function blocking antibody (HA5 or VC5), or 50  $\mu$ g/ml of LM609 (an anti- $\alpha V\beta 3$  function blocking antibody) in migration buffer, or migration buffer alone.

Cells were allowed to migrate from the upper to the lower chamber for 4 hr at 37°C. Nonmigratory cells were removed from the upper surface by wiping the upper side with an absorbant tip, and cells that had migrated to the lower side of the transwell insert were fixed for 15 min with 3.7% paraformaldehyde in PBS, then stained with a 2% crystal violet solution. After extensive water washing to remove excess crystal violet, the number of cells that had migrated were counted in three representative high power (200X) fields per insert. Data was presented as number of cells migrating +/- standard error of measurement.

### **3. In ovo chick chorioallantoic membrane (CAM) angiogenesis assay**

Ten day old embryonated chicken eggs (McIntyre Poultry; Ramona CA) were candled to illuminate blood vessels under the shell and an area with a minimum of small blood vessels is identified. The CAM was dropped away from the eggshell in this area by grinding a small hole in the mineralized shell and applying pressure to the underlying inner shell membrane. This procedure caused an

air pocket to shift from the wide end of the egg to the identified area and forcing a circular region of the CAM approximately 2 cm in diameter to drop away from the shell. A window was cut in the egg shell and a cortisone acetate pre-treated filter disc 5 mm in diameter that had been saturated in 1  $\mu$ g/ml bFGF, VEGF, TNF $\alpha$ , IL-8 (Genzyme, Inc.; Cambridge MA) or saline was placed on the CAM. The window in the shell was sealed with adhesive tape and the egg was incubated for four days.

10 A range of 0-25  $\mu$ g in 25  $\mu$ l of function blocking anti- $\alpha$ 5 $\beta$ 1 or a control non-function blocking anti- $\alpha$ 5 $\beta$ 1, 0-25  $\mu$ M in 25  $\mu$ l cyclic peptide (CRRETAWAC; SEQ ID NO: 1) or scrambled control peptide (CATAERWRC; SEQ ID NO: 2; Koivunen et al., J. Biol. Chem. 268:20205-20210 (1993); Koivunen et al., J. Cell Biol. 124:373380 (1994)), 15 0-25  $\mu$ M in 25  $\mu$ l of SJ749, an inactive control small molecule or 25  $\mu$ l of saline were applied to the growth factor saturated filter 24 hours later. Anti-fibronectin antibodies (25  $\mu$ g in 25  $\mu$ l) also were applied topically to 20 the CAM.

Fibronectin, vitronectin and fibronectin fragments (59 pmol in a final volume of 25  $\mu$ l) were applied to stimulated or unstimulated CAM's. Peptide or small molecule antagonists of  $\alpha$ 5 $\beta$ 1 (at a final serum 25 concentration of 0-25  $\mu$ M) also were injected intravenously into the chick circulation 24 hr later. CAM's were harvested on the fourth day of stimulation. Blood vessel branch points in the 5 mm filter disk area were counted at 30 X magnification in a blinded fashion as a size- 30 independent quantitative indicator of vascular sprouting in response to growth factors. Angiogenesis is characterized by the sprouting of new vessels in response to growth factors. Thus, counting of blood vessel branch points is a useful quantitative means of obtaining an 35 angiogenic index (Brooks et al., In "Methods in Molecular

Biology" (Humana Press 1999). At least ten embryos were used per treatment group. Each experiment was performed a minimum of three times.

Data was evaluated in terms of average number of blood vessel branch points per treatment group +/- standard error of measurement. Statistical analyses were performed using Student's t-test. Representative CAMS from each treatment group were photographed at 10X magnification. In some cases, CAM tissue excised from the egg was frozen in OCT (Baxter; McGraw Park IL) in liquid nitrogen, cut into 5  $\mu\text{m}$  sections, air dried and processed for immunohistochemical analysis as described in Example I, except without fixation.

#### 4. Integrin Receptor Ligand Binding Assays

Integrin  $\alpha\text{V}\beta 3$  and  $\alpha 5\beta 1$  receptor purified from human placenta were obtained from Chemicon International. Platelet integrin  $\alpha\text{IIb}\beta 3$  was purified from platelets according to established procedures. Receptors were coated (100  $\mu\text{l}$ /well) on Costar (3590) high capacity binding plates overnight at 4°C. Coating solution was discarded and plates were washed once with blocking/binding (B/B) buffer (50 mM Tris HCl, pH 7.4, 100 mM NaCl, 2mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1 mM  $\text{MnCl}_2$  and 1% BSA).

One hundred ten microliters of B/B buffer was applied for 60 min at RT. Thirty  $\mu\text{l}$  of biotinylated extracellular matrix protein ligand (fibronectin for integrin  $\alpha 5\beta 1$ , vitronectin for integrin  $\alpha\text{V}\beta 3$  and fibrinogen for integrin  $\alpha\text{IIb}\beta 3$ ) plus 50  $\mu\text{l}$  of either SJ749 in B/B buffer or B/B buffer alone were added to each well, and incubated for 25 min at RT. Plates were washed twice with B/B buffer and incubated 1 hr at RT, with anti-biotin alkaline phosphatase (100  $\mu\text{l}$ /well) in B/B buffer. Finally, plates were washed twice with B/B followed by the

addition of 100  $\mu$ l of phosphatase substrate (1.5 mg/ml). Reaction was stopped by adding 2N NaOH (25  $\mu$ l/well), and the developed color was read at 405 nm.

## B. RESULTS

- 5                   1.   Antibody specific for the cell binding  
                    domain of fibronectin inhibits attachment  
                    and migration of cells expressing  $\alpha 5\beta 1$   
                    integrin to fibronectin *in vitro* and  
                    inhibits angiogenesis *in vivo* in CAM's

10                   Since fibronectin was localized to  
                     $\alpha 5\beta 1$ -expressing blood vessels in tumors and growth factor  
                    treated tissues, the effects of fibronectin and of  
                    function blocking anti-fibronectin antibodies on  
                    angiogenesis was evaluated.

15                   An *in vitro* cell adhesion assay was used to  
                    determine, first, whether an antibody directed against the  
                    central cell binding domain peptide (anti-CBP antibody) or  
                    an antibody against an N-terminal peptide of fibronectin  
                    (anti-NT antibody) of human and chicken fibronectin  
20                   inhibited cell adhesion to fibronectin. The anti-CBP  
                    antibody significantly inhibited the adhesion to  
                    fibronectin of integrin  $\alpha 5\beta 1$  positive cells, including  
                     $\alpha 5\beta 1^+$  HT29 colon carcinoma cells, CEF's, and HUVEC's.  
                    HUVEC adhesion was blocked 70 +/- 3% by the anti-CBP  
25                   antibody. In contrast, the anti-NT antibody was  
                    ineffective in blocking cell adhesion to fibronectin.  
                    These results demonstrate that the CBP domain of  
                    fibronectin is required for adhesion of cells expressing  
                     $\alpha 5\beta 1$  integrin.

30                   Function-blocking monoclonal antibody  
                    antagonists of integrin  $\alpha 5\beta 1$ , but not control  
                    (non-function blocking) anti- $\alpha 5\beta 1$  integrin monoclonal

antibodies, selectively inhibited HT29  $\alpha 5^+$  (100 +/- 6%), CEF (89.7 +/- 3.4%), and HUVEC (72 +/- 2.5%) adhesion to fibronectin, but did not inhibit attachment to vitronectin; however, LM609, an anti- $\alpha V\beta 3$  specific  
5 antibody inhibited attachment of the cells to vitronectin. These results demonstrate that  $\alpha 5\beta 1$  binding to fibronectin is required for adhesion  $\alpha 5\beta 1$  expressing cells to fibronectin.

As angiogenesis depends in part on endothelial  
10 cell migration and invasion, the ability of anti- $\alpha 5\beta 1$  antibodies to block HUVEC migration also was evaluated. Migration of HUVEC's on fibronectin was significantly inhibited (87 +/- 2%) by function blocking antibodies directed against integrin  $\alpha 5\beta 1$ , whereas this antibody did  
15 not affect endothelial cell migration on other matrix proteins, including collagen. These results demonstrate that  $\alpha 5\beta 1$  integrin also is involved in fibronectin mediated cell migration.

The roles of fibronectin and of  $\alpha 5\beta 1$  on  
20 angiogenesis was examined *in vivo* was examined using the CAM assay. To assess the role of fibronectin in angiogenesis *in vivo*, CAM's from ten day old embryos were stimulated with bFGF or VEGF. Twenty-four hr later, anti-fibronectin antibodies were directly applied to the CAM's,  
25 then, two days later, CAM's were excised and blood vessels were quantified by counting vessel branch points.

The anti-CBP antibody inhibited the growth of new blood vessels induced by bFGF by 75 +/- 10% ( $p=0.002$ ), whereas the anti-NT antibody had a only minimal effect  
30 (34 +/- 15% inhibition,  $p=0.02$ ). The anti-CBP antibody also inhibited VEGF angiogenesis by 71 +/- 7% ( $p=0.02$ ), as did the anti-NT antibody (89 +/- 17% inhibition,  $p=0.035$ ). In contrast to anti-fibronectin antibodies, function

blocking antibodies directed against vitronectin had no significant effect on angiogenesis. These results indicate that the cell-binding domain of fibronectin plays a critical role in angiogenesis, and that the N-terminal  
5 domain of fibronectin also may contribute to some angiogenesis.

To further demonstrate a specific functional association between fibronectin and angiogenesis stimulation, fibronectin and vitronectin were directly  
10 applied to the CAM's of ten day old embryos in the presence or absence of growth factors. In the absence of growth factor addition, neither fibronectin nor vitronectin promoted angiogenesis. Equimolar amounts of intact human fibronectin, a 120 kD fragment of fibronectin  
15 with the RGD containing cell binding domain or a 40 kD C-terminal chymotryptic fibronectin fragment which lacks the RGD containing cell-binding domain (Chemicon; Temecula CA) were applied to bFGF stimulated CAM's and angiogenesis was examined.

20 Intact fibronectin enhanced growth factor stimulated angiogenesis at least  $46 \pm 11\%$  ( $p = 0.04$ ). The 120 kD cell binding fragment of fibronectin also significantly enhanced angiogenesis ( $65 \pm 20\%$ ;  $p = 0.05$ ); in contrast, the 40 kD fragment of fibronectin had no  
25 significant effect. Furthermore, anti- $\alpha 5\beta 1$  integrin antibodies reversed this process, demonstrating that fibronectin-enhanced angiogenesis was dependent on integrin  $\alpha 5\beta 1$  activity (see below). Application of vitronectin to bFGF stimulated CAM's had no effect on  
30 vessel number. Addition of fibronectin or vitronectin to VEGF stimulated CAM's also did not potentiate the angiogenic effect of VEGF. These results demonstrate that fibronectin and the endothelial cell integrin  $\alpha 5\beta 1$  have functional roles in growth factor-induced angiogenesis.



The ability of anti- $\alpha 5\beta 1$  antibodies to impact growth factor-induced angiogenesis on the chick CAM also was examined. Twenty-four hr after stimulating angiogenesis with bFGF, anti- $\alpha 5\beta 1$  antibodies were directly  
5 applied to the growth factor saturated filter disk or were injected intravenously into the embryonic circulation. The antibody antagonists of integrin  $\alpha 5\beta 1$  blocked bFGF-induced angiogenesis on the CAM by at least 88 +/- 6% (p=0.01), whereas control non-function blocking anti- $\alpha 5\beta 1$   
10 antibodies had no significant effect. Applications of function-blocking or control anti- $\alpha 5\beta 1$  antibodies to unstimulated CAM's had no effect on the number or integrity of blood vessels present within the application area. Similarly, anti- $\alpha V\beta 3$  antibody also blocked  
15 angiogenesis induced by bFGF by 65 +/- 10% (p=0.008).

Distinct growth factors can induce selective pathways of angiogenesis that activate or utilize distinct integrins. For example, integrin  $\alpha V\beta 3$  participates in the bFGF and  $TNF\alpha$  pathways of angiogenesis, while  $\alpha V\beta 5$   
20 participates in the VEGF and  $TGF\alpha$  pathways. Accordingly, the role of other integrins in growth factor induced angiogenesis was examined further.

When angiogenesis was stimulated with  $TNF\alpha$  or IL-8, anti- $\alpha 5\beta 1$  antibodies blocked angiogenesis by an  
25 average of 70.4 +/- 12% (p=0.04) and 85 +/- 4.8% (p<0.0001), respectively, and, in some experiments anti- $\alpha 5\beta 1$  antibodies inhibited  $TNF\alpha$  and IL-8 angiogenesis by up to 99 +/- 5% (p=0.005). Similarly, antibody antagonists of integrin  $\alpha V\beta 3$  blocked  $TNF\alpha$  and IL-8  
30 angiogenesis by 93.6 +/- 6.2% (p=0.004) and 77 +/- 5.2% (p=0.0001), respectively. However, when angiogenesis was induced with VEGF, antibody antagonists of integrin  $\alpha 5\beta 1$  failed to block angiogenesis, whereas anti- $\alpha V\beta 5$  antibody blocked VEGF-induced angiogenesis by 99 +/- 0.1%  
35 (p=0.004). When anti- $\alpha 5\beta 1$  integrin and anti- $\alpha V\beta 3$  integrin

antibodies were applied in combination to bFGF stimulated CAM's, no additive or synergistic inhibitory effects were observed, suggesting that these integrins participate in the same angiogenic pathway.

5           These results demonstrate that an interaction of  $\alpha 5\beta 1$  integrin with the cell-binding domain of fibronectin is involved in growth factor-induced angiogenesis *in vivo*, and that an anti- $\alpha 5\beta 1$  antibody can interfere with such angiogenesis. The results also  
10 indicate that integrin  $\alpha 5\beta 1$  regulates the same pathway of angiogenesis as does  $\alpha V\beta 3$  and that this pathway is distinct from that regulated by  $\alpha V\beta 5$ .

2.   **Peptide and nonpeptide small organic  
15           molecule  $\alpha 5\beta 1$  antagonists inhibit  
          attachment and migration of cells  
          expressing  $\alpha 5\beta 1$  integrin to fibronectin  
          *in vitro* and inhibit angiogenesis *in vivo*  
          in CAM's.**

20           The ability of peptide and nonpeptide small organic molecule antagonists of  $\alpha 5\beta 1$  integrin to interfere with cell interactions with fibronectin and with growth factor induced angiogenesis also was examined.

Non-antibody antagonists of integrin  $\alpha 5\beta 1$   
25   potently inhibited cell attachment to fibronectin. The selective cyclic peptide antagonist of integrin  $\alpha 5\beta 1$ , CRRETAWAC (SEQ ID NO: 1), significantly inhibited adhesion of  $\alpha 5^+$  HT29 colon carcinoma cells, CEF's and HUVEC's to fibronectin, but not to vitronectin, whereas a "scrambled"  
30 control peptide (CATAERWRC; SEQ ID NO: 2) had little effect on cell adhesion to either fibronectin or vitronectin. CRRETAWAC (SEQ ID NO: 1), but not the control peptide, also interfered with endothelial cell

migration on fibronectin, but not on other matrix proteins such as collagen. The cyclic peptide antagonist of  $\alpha 5 \beta 1$  also significantly blocked bFGF-induced angiogenesis (90 +/- 6%;  $p < 0.0001$ ), whereas control peptides did not inhibit angiogenesis. The peptide antagonists of integrin  $\alpha 5 \beta 1$  failed to block VEGF angiogenesis.

The  $\alpha 5 \beta 1$  selective nonpeptide small organic molecule antagonist, SJ749, blocked the adhesion of these cells to fibronectin in a concentration-dependent manner (half maximal inhibitory concentration of 0.8  $\mu\text{M}$  for  $\alpha 5^+$  HT29 cells; Figure 1), but was ineffective in blocking cell attachment to vitronectin or other extracellular matrix ligands. SJ749 also selectively inhibited ligand binding to  $\alpha 5 \beta 1$  and was substantially less effective in blocking ligand binding to  $\alpha V \beta 3$  and other integrins. The nonpeptide small organic molecule antagonist of integrin  $\alpha 5 \beta 1$  also was highly effective in blocking endothelial cell migration on fibronectin, but not on other matrix proteins such as collagen. SJ749 also blocked bFGF-induced angiogenesis on chick CAM's in a dose-dependent manner when applied either topically or systemically (Figure 2), whereas control nonpeptide molecules did not inhibit angiogenesis, even at the highest dose tested. Like the other  $\alpha 5 \beta 1$  antagonists, SJ749 did not block VEGF angiogenesis.

These results demonstrate that peptide and nonpeptide small organic molecule antagonists of  $\alpha 5 \beta 1$  significantly and selectively interfere with the function of human and chick  $\alpha 5 \beta 1$ , similarly to anti- $\alpha 5 \beta 1$  antibodies. More specifically, systemic administration of antibody, peptide and nonpeptide small molecule antagonists inhibited growth factor-induced angiogenesis with  $\text{IC}_{50}$ 's of approximately 5  $\mu\text{g}$ , 120 pmoles and 15 pmoles, respectively, per 2 ml blood volume of the chick embryos. These results also confirm that the

fibronectin receptor integrin  $\alpha 5\beta 1$  contributes to growth factor angiogenesis on the CAM.

### EXAMPLE III

#### $\alpha 5\beta 1$ ANTAGONISTS INHIBIT GROWTH FACTOR INDUCED

#### 5           ANGIOGENESIS IN HUMAN SKIN IN SCID MICE

This example demonstrates that  $\alpha 5\beta 1$  antagonists inhibit angiogenesis in human skin grown in SCID mice.

Engraftment of SCID mice with human skins was performed as previously described (Brooks et al., J. Clin. Invest. 96:1815-1822 (1995)). SCID mice were engrafted with an 8 mm x 13 mm piece of human neonatal foreskin. Fresh human neonatal foreskins were obtained from the Cooperative Human Tissue Network of the National Institutes of Health and were stored in RPMI-1640 medium supplemented with 2% fetal bovine serum and 1% gentamicin.

Four weeks after engraftment, after the skin had completely healed, 50  $\mu$ l of growth factor depleted matrigel (Becton Dickenson; Bedford MA) reconstituted with 1  $\mu$ g/ml basic fibroblast growth factor (bFGF), with 1  $\mu$ g/ml bFGF containing 25  $\mu$ g/ml anti- $\alpha 5\beta 1$  function blocking monoclonal antibody or with 1  $\mu$ g/ml bFGF containing 25  $\mu$ g/ml non-function blocking anti- $\alpha 5\beta 1$  monoclonal antibody was injected intradermally in the center of each engrafted skin. Three days later, the human skin was excised from the mouse. Boundaries were easily observed since the human skin was pink and hairless; the mouse skin was covered with white fur. The human skin was embedded in freezing medium, frozen and sectioned. Sections were stained for the presence of human blood vessels with anti-CD31, as described in Immunohistochemical analyses of blood vessel densities. Data was presented as mean CD31 positive blood vessel

numbers per 100X microscopic field, +/- standard error of measurement. Statistical analyses were performed using Student's t-test.

Human neonatal foreskin engrafted onto SCID  
5 mice was injected intradermally with growth factor  
depleted basement membrane impregnated with bFGF in the  
presence or absence of the function-blocking and control  
anti- $\alpha 5\beta 1$  antibodies. Analysis of the human skin after  
three days for the presence of human CD31 positive blood  
10 vessels. The addition of function-blocking  $\alpha 5\beta 1$  antibody  
selectively blocked angiogenesis induced by the growth  
factor, and reduced the number of CD31 positive blood  
vessels per high power field by 94 +/- 4.7% (P= 0.006).

These results demonstrate that integrin  $\alpha 5\beta 1$   
15 has a functional role in the angiogenic response to growth  
factors of human blood vessels, and that an antagonist of  
 $\alpha 5\beta 1$  binding can reduce or inhibit growth factor  
stimulated angiogenesis in human skin.

#### EXAMPLE IV

##### 20 $\alpha 5\beta 1$ ANTAGONISTS INHIBIT TUMOR GROWTH

This example demonstrates that  $\alpha 5\beta 1$  antagonists  
inhibit angiogenesis in human tumors in a CAM model  
system.

The chick CAM tumor assay was performed by  
25 placing ten million tumor cells on the surface of a CAM,  
and culturing the cells for one week. The resulting  
tumors were excised and cut into 50 mg fragments. These  
fragments were placed on additional CAM's and treated  
topically the following day with 25  $\mu\text{g}$  in 25  $\mu\text{l}$  of  
30 anti- $\alpha 5\beta 1$  or a control non-function blocking anti- $\alpha 5\beta 1$ , or  
systemically by intravenous injection with a final serum

concentration of 25  $\mu$ M cyclic peptides or 25  $\mu$ M SJ7549 and 25  $\mu$ M scrambled control peptide or 25  $\mu$ M inactive small molecule or 25  $\mu$ l of saline (blood volume of chick embryo is approximately 2 ml). Forty-eight hours later, CAM's 5 were excised from the egg and the number of blood vessels entering the tumors were counted (as vessel branch points).

Data was presented as mean blood vessel number per treatment group (+/- standard error of measurement). 10 Each treatment group incorporated at least ten tumors per experiment. Representative tumors were photographed at 10X magnification. Tumors were excised from the egg and tumor weights were determined for each tumor. Data was presented as mean tumor weight per treatment group 15 (+/- standard error of measurement). Statistical analyses were performed using Student's t-test.

HT29 colon carcinoma cells lacking  $\alpha 5\beta 1$  expression were grown on the CAM's of 10-day old embryos. These tumor cells secrete several angiogenic growth 20 factors, including VEGF, TGF $\alpha$ , TGF $\beta$ , TNF $\alpha$ , and IL-8 (Anzano et al., Cancer Res. 49:2898-2904 (1989); Varner et. al., *supra*, 1995; Ellis et al., J. Biol. Chem. 273:1052-1057 (1998)). Integrin  $\alpha 5\beta 1$  negative tumor cells were used to distinguish the potential anti-tumor effects 25 from anti-vasculature effects of integrin  $\alpha 5\beta 1$  antagonists.

Treatment with function-blocking, but not control, antibodies significant reduced (70 +/- 10%, p=0.02) the number of tumor-associated blood vessels. No 30 significant morphological or quantitative difference was observed between saline and control antibody treated tumors or their associated blood vessels. Furthermore, treatment with function-blocking anti- $\alpha 5\beta 1$  antibodies

resulted in tumor regression. Anti- $\alpha 5\beta 1$  treated tumors were 32% smaller than control treated tumors ( $p=0.02$ ).

Intravenous administration of cyclic peptide inhibitors of integrin  $\alpha 5\beta 1$  and nonpeptide small molecule inhibitors of integrin  $\alpha 5\beta 1$  also induced tumor regression on the CAM, whereas control peptide or control nonpeptide treated tumors continued to increase in size. Tumors treated with peptide and nonpeptide inhibitors were 31% and 51% smaller than control treated tumors, respectively ( $p=0.003$ ). Tumor cells remained integrin  $\alpha 5\beta 1$  negative throughout the course of the experiment, indicating that the anti-tumor effects were based on the targeting of the tumor associated blood vessels.

The effect of  $\alpha 5\beta 1$  antagonists on tumor angiogenesis in  $\alpha 5\beta 1^+$  Hep 3 squamous carcinoma cells also was examined. Treatment of the tumors with function-blocking anti- $\alpha 5\beta 1$  resulted in tumor regression, with the tumors being 45% smaller than control tumors ( $p=0.046$ ). No significant morphological or quantitative differences were observed between saline and control antibody treated tumors.

These results demonstrate that targeting vascular cell integrin  $\alpha 5\beta 1$  inhibits tumor angiogenesis and tumor growth, and that antagonists of integrin  $\alpha 5\beta 1$  are potent inhibitors of tumor growth and tumor-induced angiogenesis.

Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made with departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

What is claimed is:

1. A method of reducing or inhibiting angiogenesis in a tissue, comprising contacting  $\alpha 5\beta 1$  integrin in the tissue with an agent that interferes with specific binding of the  $\alpha 5\beta 1$  integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue.
2. The method of claim 1, wherein the agent does not substantially interfere with the specific binding of a ligand to an integrin other than  $\alpha 5\beta 1$  integrin to its ligand.
3. The method of claim 1, wherein the ligand is fibronectin.
4. The method of claim 1, wherein the tissue comprises ocular tissue.
5. The method of claim 4, wherein the ocular tissue is selected from the group consisting of retina, macula and cornea.
6. The method of claim 1, wherein the tissue comprises skin.
7. The method of claim 1, wherein the tissue comprises synovial tissue.
8. The method of claim 1, wherein the tissue comprises bone.
9. The method of claim 1, wherein the tissue comprises a neoplasm.



10. The method of claim 9, wherein the neoplasm is a malignant neoplasm.

11. The method of claim 10, wherein the malignant neoplasm is a metastatic malignant neoplasm.

5 12. The method of claim 10, wherein the malignant neoplasm is a carcinoma.

13. The method of claim 1, wherein the agent comprises a peptide.

14. The method of claim 13, wherein the  
10 peptide comprises the amino acid sequence CRRETAWAC (SEQ ID NO: 1).

15. The method of claim 1, wherein the agent comprises an anti- $\alpha 5\beta 1$  integrin antibody or an  $\alpha 5\beta 1$  integrin binding fragment of said antibody.

15 16. The method of claim 1, wherein the agent comprises a nonpeptide organic molecule.

17. The method of claim 16, wherein the nonpeptide organic molecule is a heterocycle having the general structure (S)-2-phenylsulfonylamino-3-  
20 {{{8-(2-pyridinyl aminomethyl)}-1-oxa-2-azaspiro-{4,5}-dec-2-en-yl} carbonylamino}propionic acid.

18. The method of claim 16, wherein the nonpeptide organic molecule comprises  
(S)-2-{(2,4,6-trimethylphenyl)sulfonyl}amino-3-  
25 {7-benzoyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxy-2,7-diazaspiro-{4,4}-non-2-en-3-yl}carbonylamino}propionic acid.

19. The method of claim 1, wherein the agent is linked to a cytotoxin.

20. The method of claim 19, wherein the cytotoxin is a cancer chemotherapeutic drug.

5 21. A method of identifying the presence of angiogenesis in a tissue, comprising the steps of:

a) contacting the tissue with an agent that specifically binds  $\alpha 5\beta 1$  integrin, and

10 b) detecting specific binding of the agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in the tissue, thereby identifying the presence of angiogenesis in the tissue.

22. The method of claim 21, wherein the agent comprises a peptide.

15 23. The method of claim 21, wherein the agent comprises the amino acid sequence CRRETAWAC (SEQ ID NO: 1).

20 24. The method of claim 21, wherein the agent comprises an anti- $\alpha 5\beta 1$  integrin antibody or an  $\alpha 5\beta 1$  integrin binding fragment of said antibody.

25 25. The method of claim 21, wherein the agent comprises a nonpeptide organic molecule.

26. The method of claim 25, wherein the nonpeptide organic molecule is a heterocycle having the general structure (S)-2-phenylsulfonylamino-3-  
25 {{{8-(2-pyridinyl aminomethyl)}-1-oxa-2-azaspiro-  
{4,5}-dec-2-en-yl} carbonylamino}propionic acid.

27. The method of claim 25, wherein the non-peptide organic molecule comprises (S)-2-((2,4,6-trimethylphenyl)sulfonyl)amino-3-(7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxy-2,7-diazaspiro-{4,4}-non-2-en-3-yl)carbonylamino} propionic acid.

28. The method of claim 21, wherein the agent further comprises a detectable label.

29. The method of claim 21, wherein detecting specific binding of the agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in the tissue comprises the steps of:

a) contacting the agent, which is specifically bound to  $\alpha 5\beta 1$  integrin, with a reagent that specifically interacts the agent, and

b) detecting interaction of the reagent, thereby detecting specific binding of the agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in the tissue.

30. The method of claim 21, wherein the tissue is selected from the group consisting of embryonic tissue and placental tissue.

31. The method of claim 21, wherein the tissue comprises granulation tissue.

32. The method of claim 21, wherein the tissue is involved in a pathological condition.

33. The method of claim 32, wherein the pathological condition comprises a neoplasm.

34. The method of claim 32, wherein the tissue comprises ocular tissue.

35. A method of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual, comprising the steps of:

a) obtaining a sample of the tissue from the individual, wherein, in an individual having the pathological condition, the tissue exhibits angiogenesis;

10           b) contacting the sample with an agent that specifically binds  $\alpha 5\beta 1$  integrin; and

15           c) detecting specific binding of the agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in the tissue, thereby diagnosing a pathological condition characterized by angiogenesis in the individual.

36. The method of claim 35, wherein the pathological condition involves the eye.

20           37. The method of claim 36, wherein the pathological condition is selected from the group consisting of diabetic retinopathy and macular degeneration by neovascularization.

38. The method of claim 35, wherein the pathological condition involves the skin.

25           39. The method of claim 38, wherein the pathological condition is selected from the group consisting of a hemangioma and psoriasis.

40. The method of claim 35, wherein the pathological condition involves a joint.

41. The method of claim 40, wherein the pathological condition is selected from the group consisting of rheumatoid arthritis and osteoarthritis.

42. The method of claim 33, wherein the pathological condition involves a neoplasm.

43. The method of claim 42, wherein the neoplasm is a malignant neoplasm.

44. The method of claim 43, wherein the malignant neoplasm is a metastatic malignant neoplasm.

45. The method of claim 43, wherein the malignant neoplasm is a carcinoma.

46. The method of claim 45, wherein the carcinoma is selected from the group consisting of breast carcinoma, colon carcinoma, ovarian carcinoma, and pancreatic carcinoma.

47. A method of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual, comprising the steps of:

a) administering an agent that specifically binds  $\alpha 5 \beta 1$  integrin to an individual suspected of having the pathological condition; and

5           b) detecting specific binding of the agent  
to  $\alpha 5\beta 1$  integrin associated with a blood vessel  
in the tissue, thereby diagnosing a  
pathological condition characterized by  
angiogenesis in the individual.

48. The method of claim 47, wherein the agent  
is detectably labeled.

49. The method of claim 48, wherein detecting  
specific binding of the agent is performed using an  
10 *in vivo* imaging method.

50. The method of claim 48, wherein the  
detectably labeled agent comprises the agent linked to a  
label selected from the group consisting of a  
radionuclide, a paramagnetic material and an X-ray  
15 attenuating material.

51. The method of claim 49, wherein the  
*in vivo* imaging method is selected from the group  
consisting of radionuclide imaging, positron emission  
tomography, computerized axial tomography, and magnetic  
20 resonance imaging.

52. The method of claim 48, wherein detecting  
specific binding of the agent to  $\alpha 5\beta 1$  integrin associated  
with a blood vessel in the tissue comprises the steps of:

25           a) obtaining a sample of the tissue from  
the individual; and

          b) detecting specific binding of the agent  
in the sample.

53. The method of claim 47, wherein detecting specific binding of the agent to  $\alpha 5 \beta 1$  integrin associated with a blood vessel in the tissue comprises the steps of:

5

b) contacting the agent that is specifically bound to  $\alpha 5\beta 1$  integrin with a reagent that specifically interacts with the agent; and

10

15

20

56. The method of claim 55, wherein the individual is a human.

57. A method of reducing the severity of a pathological condition associated with angiogenesis in an individual, comprising administering to the individual an agent that interferes with specific binding of  $\alpha 5\beta 1$  integrin to a ligand in a tissue associated with the pathological condition, thereby reducing or inhibiting angiogenesis in the tissue, and reducing the severity of the pathological condition.

58. The method of claim 57, wherein the pathological condition is a neoplasm.

59. The method of claim 58, wherein the neoplasm is a malignant neoplasm.

60. The method of claim 59, wherein the malignant neoplasm is a metastatic malignant neoplasm.

61. The method of claim 59, wherein the malignant neoplasm is a carcinoma.

62. The method of claim 61, wherein the carcinoma is selected from the group consisting of a breast carcinoma, a colon carcinoma, an ovarian carcinoma and a pancreatic carcinoma.

63. The method of claim 59, wherein the malignant neoplasm is selected from the group consisting of a sarcoma, a mesothelioma, a teratocarcinoma, an astrocytoma, and a glioblastoma.

64. The method of claim 57, wherein the individual is a human.

65. The method of claim 57, wherein the agent is administered intravenously.



66. The method of claim 57, wherein the agent is administered orally.

67. The method of claim 58, wherein the agent is administered into a neoplasm.

5           68. The method of claim 57, wherein the  
pathological condition is associated with the eye.

69. The method of claim 68, wherein the pathological condition is selected from the group consisting of diabetic retinopathy and macular  
10 degeneration by neovascularization.

70. The method of claim 68, wherein the agent is administered in the form of eye drops.

71. The method of claim 68, wherein the agent is administered intravenously.

15                   72. The method of claim 68, wherein the agent  
is administered orally.

73. The method of claim 57, wherein the pathological condition is associated with a joint.

74. The method of claim 73, wherein the agent  
20 is administered intrasynovially.

75. The method of claim 57, wherein the agent is administered at a dose of 0.0001 to 100 mg/kg body weight.

76. A method of identifying an agent that reduces or inhibits angiogenesis associated with  $\alpha 5\beta 1$  integrin expression in a tissue, comprising the steps of:

5 a) contacting a tissue exhibiting angiogenesis associated with  $\alpha 5\beta 1$  integrin expression with an agent; and

10 b) detecting a reduction or inhibition of angiogenesis in the tissue, thereby identifying an agent that reduces or inhibits angiogenesis associated with  $\alpha 5\beta 1$  integrin expression in a tissue.

77. The method of claim 76, wherein contacting the tissue occurs *in vivo*.

15 78. The method of claim 76, wherein contacting the tissue occurs *ex vivo*.

79. The method of claim 76, wherein the tissue comprises malignant neoplastic tissue.

**ABSTRACT OF THE INVENTION****METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS**

The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by

5 contacting  $\alpha 5\beta 1$  integrin in the tissue with an agent that interferes with specific binding of the  $\alpha 5\beta 1$  integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds  $\alpha 5\beta 1$  integrin, and detecting

10 specific binding of the agent to  $\alpha 5\beta 1$  integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of

15 reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of  $\alpha 5\beta 1$  integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition

20 associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of  $\alpha 5\beta 1$  integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent

25 that reduces or inhibits angiogenesis associated with  $\alpha 5\beta 1$  integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with  $\alpha 5\beta 1$  integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue.




FIG. 1




FIG. 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION FOR  
UTILITY OR DESIGN  
PATENT APPLICATIONDeclaration  
Submitted with  
Initial FilingDeclaration  
Submitted after  
Initial Filing

Attorney Docket

6627-PA11

First Named Inventor

Varner, Judith A.

COMPLETE IF KNOWN

Application Number

TBA

Filing Date

HEREWITH

Group Art Unit

TBA

Examiner Name

TBA

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS

(Title of the Invention)

the specification of which



is attached hereto

OR



was filed on (MM/DD/YYYY)

as United States Application Number or PCT International

Application Number

and was amended on (MM/DD/YYYY)

(if applicable.)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Numbers	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>



Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached heret
60/084,850	May 8, 1998	

## DECLARATION - Utility or Design Patent Application

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Patent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Registered practitioner(s) name/registration number listed below:

Name	Registration Number	Name	Registration Number
CARL R. BROWN NEIL F. MARTIN JOHN L. HALLER	19,587 23,088 27,795	JAMES W. MCCLAIN ELEANOR M. MUSICK RICHARD J. IMBRA	24,536 35,623 37,643

Direct all correspondence to:

Attorney Name	Richard J. Imbra				
Address	BROWN, MARTIN, HALLER & MCCLAIN, LLP				
Address	1660 UNION STREET				
City	SAN DIEGO	State	CALIFORNIA	ZIP	92101
Country	USA	Telephone	(619) 238-0999	Fax	(619) 238-0062

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])			Last Name		
Judith A.			Varnier		
Inventor's Signature	<i>Judith A. Varnier</i>		Date	May 16, 1999	
Residence: City	Encinitas	State	CA	Country	USA
Post Office Address	327 Via Andalusia				
Post Office Address					
City	Encinitas	State	CA	Zip	92024
				Country	USA

NAME OF SECOND INVENTOR: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])			Last Name		
Inventor's Signature			Date		
Residence: City		State		Country	
Post Office Address					
Post Office Address					
City		State		Zip	
				Country	

☐ Additional Inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

662050-6320260

SEQUENCE LISTING

<110> VARNER, JUDITH A.

<120> METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS

<130> 6627VARNPA11

<140> U.S.

<141> 1999-05-07

<150> 60/084,850

<151> 1998-05-08

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 1

Cys Arg Arg Glu Thr Ala Trp Ala Cys

1

5

<210> 2

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: SYNTHETIC  
PEPTIDE

<400> 2

Cys Ala Thr Ala Glu Arg Trp Arg Cys

1

5